<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        369-212-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        QUETTA 150 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUETIAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACTAVIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACTAVIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>QUETTA contains a substance called quetiapine. This belongs to a group of medicines called<br />anti- psychotics.<br />QUETTA can be used to treat several illnesses, such as:<br />- Bipolar depression: where you feel sad. You may find that you feel depressed, feel guilty, lack<br />energy, lose your appetite or can&rsquo;t sleep.<br />- Mania: where you may feel very excited, elated, agitated, enthusiastic or hyperactive or have<br />poor judgment including being aggressive or disruptive.<br />- Schizophrenia: where you may hear or feel things that are not there, believe things that are not<br />true or feel unusually suspicious, anxious, confused, guilty, tense or depressed.<br />Your doctor may continue to prescribe QUETTA even when you are feeling better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take QUETTA :<br />- if you are allergic (hypersensitive) to quetiapine or any of the other ingredients of this medicine<br />(listed in section 6).<br />- if you are taking any of the following medicines:<br />- Some medicines for HIV<br />- &lsquo;Azole&rsquo; medicines (for fungal infections)<br />- Erythromycin or clarithromycin (for infections)<br />- Nefazodone (for depression).<br />Do not take QUETTA if the above applies to you. If you are not sure, talk to your doctor or<br />pharmacist before taking QUETTA .<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking QUETTA .<br />Tell your doctor if:<br />- You or someone in your family, have or have had any heart problems, for example heart rhythm<br />problems or if you are taking any medicines that may have an impact on the way your heart beats<br />- You have low blood pressure.<br />- You have had a stroke, especially if you are elderly.<br />- You have problems with your liver.<br />- You have ever had a fit (seizure).<br />- You have diabetes or have a risk of getting diabetes. If you do, your doctor may check your blood<br />sugar levels while you are taking QUETTA .<br />- You know that you have had low levels of white blood cells in the past (which may or may not have<br />been caused by other medicines).<br />- You are an elderly person with dementia (loss of brain function). If you are, QUETTA should<br />not be taken because the group of medicines that QUETTA belongs to may increase the risk<br />of stroke, or in some cases the risk of death, in elderly people with dementia.<br />- You or someone else in your family has a history of blood clots, as medicines like these have<br />been associated with formation of blood clots.<br />While taking this medicine, tell your doctor immediately if you experience:<br />- A high temperature (fever), stiff muscles, feeling of being confused and changes in<br />consciousness. These might be signs of a so-called &lsquo;neuroleptic malignant syndrome&rsquo;.<br />- Involuntary and abnormal movements, especially of the tongue, mouth and jaw, facial grimacing,<br />rapid eye blinking and uncontrollable movements of arms, legs, fingers and toes. These might be<br />symptoms of &lsquo;tardive dyskinesia&rsquo;.<br />- Tremor, twisting and repetitive movements or abnormal body posture, slurred speech,<br />restlessness and stiff muscles. These might be symptoms of &lsquo;extrapyramidal symptoms&rsquo;.<br />- Dizziness or a feeling of severe sleepiness. This could increase the risk of accidental injury (fall),<br />especially in elderly patients.<br />- Trouble swallowing.<br />- Weight gain. Your doctor might need to monitor your treatment more closely.<br />- Fits (seizures).<br />- A long-lasting and painful erection (priapism).<br />These conditions can be caused by this type of medicine and your doctor might need to reduce<br />your dose or discontinue treatment.<br />Thoughts of suicide and worsening of your depression<br />If you are depressed you may sometimes have thoughts of harming or killing yourself. These may<br />be increased when first starting treatment, since these medicines all take time to work, usually<br />about two weeks but sometimes longer. These thoughts may also be increased if you suddenly<br />stop taking your medication.<br />You may be more likely to think like this if you are a young adult. Information from clinical trials has<br />shown an increased risk of suicidal thoughts and/or suicidal behaviour in young adults aged less<br />than 25 years with depression.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital<br />straight away. You may find it helpful to tell a relative or close friend that you are depressed, and<br />ask them to read this leaflet. You might ask them to tell you if they think your depression is getting<br />worse, or if they are worried about changes in your behaviour.<br />Children and adolescents<br />QUETTA should not be used in children and adolescent below 18 years of age due to higher<br />risk of side effects.<br />Other medicines and QUETTA<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other<br />medicines.<br />Do not take QUETTA if you are taking any of the following medicines:<br />- Some medicines for HIV<br />- &lsquo;Azole&rsquo; medicines (for fungal infections)<br />- Erythromycin or clarithromycin (for infections)<br />- Nefazodone (for depression).<br />Tell your doctor if you are taking any of the following medicines:<br />- Epilepsy medicines (like phenytoin or carbamazepine)<br />- High blood pressure medicines<br />- Medicines which act on the central nervous system<br />- Thioridazine (a medicine to treat psychiatric disorders)<br />- Medicines that have an impact on the way your heart beats, for example, drugs that can cause an<br />imbalance in electrolytes (low levels of potassium or magnesium) such as diuretics (water pills)<br />or certain antibiotics (drugs to treat infections).<br />If you are not sure about what type of medicines you are taking, talk to your doctor or pharmacist<br />before taking QUETTA .<br />QUETTA with food, drink and alcohol<br />QUETTA can be taken with or without food.<br />You should be careful how much alcohol you drink. The combined effect of QUETTA and<br />alcohol might make you feel drowsy.<br />Do not drink grapefruit juice while you are taking QUETTA. It can affect the way the medicine<br />works.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby,<br />ask your doctor or pharmacist for advice before taking this medicine.<br />- You should not take QUETTA during pregnancy unless this has been discussed with your<br />doctor.<br />- QUETTA should not be taken if you are breast-feeding.<br />The following symptoms may occur in newborn babies, of mothers that have used quetiapine in the<br />last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness,<br />sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of<br />these symptoms you may need to contact your doctor.<br />Driving and using machines<br />Your tablets may make you feel sleepy. Do not drive or use any tools or machines until you know<br />how the tablets affect you.<br />QUETTA contains lactose<br />QUETTA contains lactose which is a type of sugar. If you have been told by your doctor that<br />you have an intolerance to some sugars, contact your doctor before taking this medicinal product.<br />Effect on urine drug screens<br />If you are having a urine drug screen, taking QUETTA may cause positive results for methadone<br />or certain drugs for depression called tricyclic antidepressants (TCAs) when some test methods<br />are used, even though you may not be taking methadone or TCAs. If this happens, a more specific<br />test can be performed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist<br />if you are not sure.<br />Dosage<br />Your doctor will decide on your starting dose. The maintenance dose (daily dose) will depend on<br />your illness and needs but will usually be between 150 mg and 800 mg.<br />You will take your tablets once a day, at bedtime, or twice a day, depending on your illness.<br />Method of administration<br />- Swallow your tablets whole with a drink of water.<br />- You can take your tablets with or without food.<br />- Do not drink grapefruit juice while you are taking QUETTA . It can affect the way the medicine<br />works.<br />- Do not stop taking your tablets even if you feel better, unless your doctor tells you.<br />Liver problems<br />If you have liver problems your doctor may change your dose.<br />Elderly people<br />If you are elderly your doctor may change your dose.<br />Use in children and adolescents<br />QUETTA should not be used in children and adolescents below 18 years of age.<br />If you take more QUETTA than you should<br />If you take more QUETTA than prescribed by your doctor, you may feel sleepy, feel dizzy and<br />experience abnormal heart beats. Contact your doctor or nearest hospital straight away. Take the<br />tablets, leaflet and/or carton with you so the doctor will know what you took.<br />If you forget to take QUETTA<br />If you miss a dose, take that dose as soon as you remember. If it is almost time to take the next<br />dose, wait until then. Do not take a double dose to make up for a forgotten tablet.<br />If you stop taking QUETTA<br />Do not stop taking your tablets even if you are feeling better, unless your doctor tells you. If you<br />suddenly stop taking QUETTA you may be unable to sleep (insomnia), or you may feel sick<br />(nausea), or you may experience headache, diarrhea, being sick (vomiting), dizziness or irritability.<br />Your doctor may suggest you reduce the dose gradually before stopping treatment.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If any of the following occurs, stop taking QUETTA and contact a doctor or go to the<br />nearest hospital straight away, as you may need urgent medical attention:<br />Uncommon (may affect up to 1 in 100 people):<br />- Allergic reactions that may include raised lumps (wheals), swelling of the skin and swelling<br />around the mouth<br />- Fits or seizures<br />- Uncontrollable movements, mainly of your tongue, mouth and jaw, but also of arms, legs, fingers<br />and toes, facial grimacing and rapid eye blinking. These might be symptoms of a condition called<br />&lsquo;tardive dyskinesia&rsquo;.<br />Rare (may affect up to 1 in 1,000 people):<br />- A combination of high temperature (fever), sweating, stiff muscles, feeling very drowsy or faint,<br />large increase in blood pressure and fast heartbeat (a disorder called &lsquo;neuroleptic malignant<br />syndrome&rsquo;)</p><p>- Yellowing of the skin and eyes (jaundice)<br />- Inflammation of the liver (hepatitis)<br />- A long-lasting and painful erection (priapism)<br />- Blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in<br />the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in<br />breathing<br />- Inflammation of the pancreas (pancreatitis). Symptoms can include severe pain in the abdomen<br />and back, nausea and vomiting.<br />Very rare (may affect up to 1 in 10,000 people):<br />- A severe allergic reaction (called anaphylaxis) which may cause difficulty in breathing or shock<br />- Rapid swelling of the skin, usually around the eyes, lips and throat (angioedema)<br />- Severe rash, blisters, or red patches on the skin (Stevens-Johnson syndrome)<br />- Abnormal muscle breakdown (rhabdomyolysis) with symptoms such as muscle pain, weakness<br />and swelling which can lead to kidney problems (urine can become dark).<br />Not known (frequency cannot be estimated from the available data):<br />- Severe skin conditions called &lsquo;toxic epidermal necrolysis&rsquo; (severe rash involving reddening,<br />peeling and swelling of the skin that resembles severe burns) and &lsquo;erythema multiforme&rsquo; (irregular<br />red patches on the skin of the hands and arms).<br />Other possible side effects:<br />Very common (may affect more than 1 in 10 people):<br />- Dizziness (may lead to falls), headache, dry mouth<br />- Feeling sleepy (this may go away with time, as you keep taking your tablets) (may lead to falls)<br />- Discontinuation symptoms (symptoms which occur when you stop taking QUETTA ) include<br />not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea, being sick<br />(vomiting), dizziness, and irritability<br />- Changes in the amount of certain fats (triglycerides and cholesterol) in the blood<br />- Putting on weight<br />- Decreased levels of a certain protein in red blood cells (haemoglobin).<br />Common (may affect up to 1 in 10 people):<br />- Decrease in number of certain white blood cells (leukopenia)<br />- Fainting (may lead to falls)<br />- Rapid heartbeat<br />- Awareness of unusual heartbeats (palpitations)<br />- Shortness of breath (dyspnoea)<br />- Low blood pressure when standing up, which may result in dizziness or feeling faint (may lead to<br />falls)<br />- Stuffy nose<br />- Constipation, indigestion, vomiting<br />- Extrapyramidal side effects with symptoms such as abnormal and repetitive muscle movements.<br />These include difficulty starting muscle movements, shaking, feeling restless or muscle stiffness<br />without pain<br />- Abnormal dreams and nightmares<br />- Thoughts of suicide and worsening of your depression<br />- Increased appetite<br />- Disturbance in speech and language<br />- Increases in the amount of the hormone prolactin in the blood. In rare cases it could lead to<br />swelling of breasts and unexpected breast milk production in both men and women. Also, it could<br />cause absence of monthly period or irregular periods in women<br />- Blurred vision<br />- Feeling irritated<br />- Fever<br />- Changes as seen in blood tests, such as increased levels of liver enzymes, decrease or increase<br />in white blood cells (neutrophils or eosinophils, respectively), changes in the amount of thyroid<br />hormones (total T4, free T4, total T3, TSH) and increase in blood sugar (glucose)<br />- Feeling weak<br />- Swelling of arms or legs.<br />Uncommon (may affect up to 1 in 100 people):<br />- Restless legs syndrome (unpleasant sensation in the legs)<br />- Difficulty swallowing<br />- Heart condition called &lsquo;QT-prolongation&rsquo; which can affect your heart beat rhythm (measured with<br />an electrocardiogram)<br />- Diabetes or worsening of pre-existing diabetes<br />- Sexual dysfunction<br />- Changes as seen in blood tests, such as increase in certain enzymes (gamma-GT), decreased<br />number of red blood cells (anaemia) or platelets in the blood (thrombocytopenia), lower levels of<br />sodium in the blood (hyponatraemia) or changes of the amount of thyroid hormones (free T3) and<br />thyroid problems (hypothyroidism).<br />- Slow heartbeat<br />Rare (may affect up to 1 in 1,000 people):<br />- Swelling of breasts and unexpected production of breast milk (galactorrhoea)<br />- Menstrual disorder<br />- Metabolic syndrome (changes in your weight, blood glucose and certain fats in your blood that<br />can increase the risk of heart problems and diabetes)<br />- Sleepwalking, sleep talking and sleep related eating disorder<br />- Lowering of body temperature<br />- Increased levels of the enzyme creatine phosphokinase, decrease in certain types of white blood<br />cells (agranulocytosis) as seen in blood tests.<br />Very rare (may affect up to 1 in 10,000 people):<br />- A condition called &lsquo;Syndrome of inappropriate antidiuretic hormone secretion&rsquo; (SIADH) which<br />causes low sodium levels in your blood. That can lead to symptoms such as headache, nausea,<br />confusion and weakness.<br />Not known (frequency cannot be estimated from the available data):<br />- Decreased number of white blood cells in the blood (neutropenia).<br />The class of medicines to which QUETTA belongs can cause heart rhythm problems, which can<br />be serious and in severe cases may be fatal.<br />Additional side effects in children and adolescents<br />The same side effects that may occur in adults may also occur in children and adolescents.<br />The following side effects have been seen more often in children and adolescents than in adults or<br />have only been seen in children and adolescents:<br />Very common (may affect more than 1 in 10 people):<br />- Increase in blood pressure<br />- Increase in the amount of a hormone called prolactin, in the blood. Increases in the hormone<br />prolactin could in rare cases lead to the following:<br />- Boys and girls to have swelling of breasts and unexpectedly produce breast milk.<br />- Girls to have no monthly period or irregular periods.<br />- Increased appetite<br />- Extrapyramidal side effects with symptoms such as abnormal and repetitive muscle movements.<br />These include difficulty starting muscle movements, shaking, feeling restless or muscle stiffness<br />without pain.<br />Common (may affect up to 1 in 10 people):<br />- Feeling irritated.<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects<br />not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the carton, label and blister after<br />&lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.<br />Store below 30&deg; C.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how<br />to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is quetiapine. QUETTA film-coated tablets contain 25 mg, 100 mg, 150<br />mg, 200 mg or 300 mg quetiapine (as quetiapine fumarate).<br />- The other ingredients are:<br />Tablet core: Microcrystalline cellulose, povidone K29-32, calcium hydrogen phosphate dihydrate,<br />sodium starch glycolate (type A), lactose monohydrate, magnesium stearate.<br />Tablet coating: Hypromellose 6cP (E464), titanium dioxide (E171), lactose monohydrate, macrogol<br />3350, triacetin, iron oxide yellow (E172) (in 25 mg, 100 mg and 150 mg tablets) and iron oxide red<br />(E172) (only in the 25 mg tablets).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                QUETTA 25 mg film-coated tablet is round, 5.5 mm in diameter, biconvex, light orange and
engraved with “Q” on one side.
QUETTA 100 mg film-coated tablet is round, 8.5 mm in diameter, biconvex, yellow and
engraved with “Q” on one side.
QUETTA 150 mg film-coated tablet is oval with dimensions of 6.9 mm x 13.8 mm, biconvex,
pale yellow and engraved with “Q” on one side.
QUETTA 200 mg film-coated tablet is oval with dimensions of 16 mm x 8.2 mm, biconvex, white
and engraved with “Q” on one side.
QUETTA 300 mg film-coated tablet is oval with dimensions of 19 mm x 7.6 mm, biconvex, white
and engraved with “Q” on one side and “300” on the other side.
Pack sizes:
Blisters:
QUETTA 25 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets
QUETTA 100 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets
QUETTA 150 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets
QUETTA 200 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets
QUETTA 300 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets
Tablet containers:
QUETTA 25 mg film-coated tablets: 100, 250 tablets
QUETTA 100 mg film-coated tablets: 100, 250 tablets
QUETTA 150 mg film-coated tablets: 100, 250 tablets
QUETTA 200 mg film-coated tablets: 100, 250 tablets
QUETTA 300 mg film-coated tablets: 60, 100, 250 tablets
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by: Actavis Malta<br />for:<br />SPIMACO<br />Al-Qassim Pharmaceutical Plant<br />Saudi Pharmaceutical Industries &amp;<br />Medical Appliances Corporation<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2014.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>&nbsp;تنتمي هذه المادة لمجموعة من الأدوية التي تسمى مضادات الذهان. كويتا يحتوي على مادة تسمى كويتيابين. يستخدم كويتالعلاج العديد من الأمراض مثل:&minus;حيث قدعندما تشعر بأنك حزين. الاكتئاب ثنائي القطب: تجدنفسك تشعربالاكتئاب،الإحساسبالذنب،فقدانالطاقة،و فقدانالشهيةأوعدم استطاعة .النوم&minus;أو ابتهاج أو هياج أو حماس أو فرط فى النشاط أو لديك فقر فى تقدير حيث قد تشعر بإثارة مفرطة, نوبات الهوس: الأشياء بمافيذلككونهاعدوانيةأوتخريبية.&minus;, أو اعتقادات مرض الفصام المصاحب للأعراض التالية مثل تخيل سماع أو رؤية أو الإحساس بأشياء غير موجودة , أو شكوك غير عادية أو القلق أو الارتباك أو الشعور بالذنب أو التوتر أو الاكتئاب. خاطئة قديستمر طبيبك المعالج فى وصف كويتاحتىفى حالة شعورك&nbsp;بتحسن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول كويتا فى الحالات الآتية: &minus;)و المذكورة في ( للكويتا أو أي من المكونات الأخرى لهذا الدواء فرط الحساسيةاذا كنت تعاني من حساسية )فقرة 6.(&minus;إذا كنت تتناول أحد الأدوية التالية:&bull;أدوية نقص المناعة.&bull;&quot; وهى أدوية لعلاج العدوى الفطرية.&quot;أحد مجموعة أزول&bull;إريثروميسينأومضادات حيوية (.كلاريثروميسين )&bull;نيفازودونلعلاج الاكتئاب (.) أخبر طبيبك المعالج أو الصيدلي قبل تناول ًإذا كنت غير متأكدالا تتناول كويتا إذا كان أي مما سبق ينطبق عليك. الكويتا</p><p><strong>.تحذيرات و احتياطات</strong></p><p>:تحدث مع طبيبك أو الصيدلي قبل تناول كويتا.أخبر طبيبك فى الحالات الآتية:&minus;على سبيل المثال مشاكل تسارع أي مشاكل في القلب, ً أو مسبقاًإذا كان لديك أو لدى أحد من أفراد عائلتك حاليانبضات القلب أو كنت تتناول أي دواء له تأثير على نبض القلب.&minus;إذا كنت تعاني من انخفاض ضغط الدم.&minus; إذا كنت من كبار السن.ًإذا أصبت بجلطة , خاصة&minus;إذا كانت لديك أي مشاكل في الكبد.&minus;إذا كنت تعرضت لنوبات مرضية في أي وقت مضى.&minus;طبيبك قد يتحقق من مستويات بمرض السكري أو لديك مخاطر من الإصابة بمرض السكري , ًإذا كنت مصاباالسكر في الدم لديك خلال تناولك لكويتا.&minus;و التي قد تكون أو لا تكون إذا كنت تعلم أنه كان لديك في الماضي مستويات منخفضة من كريات الدم البيضاء ) لتناول أدوية أخرى(ًسببا&minus;, لأن مجموعة الأدوية التي ينتمي إذا كنت من كبار السن المصابين بالخرف يجب عليك ألا تتناول الكويتا إليها كويتا يمكن أن تزيد من خطر حدوث الجلطة أو في بعض الحالات تزيد من خطر الوفاة عند الرجال الكبار في السن المصابين بالخرف&minus;حيث ارتبطت هذا النوعية من إذا كان لديك أو لدى أحد من أفراد عائلتك تاريخ من التعرض لجلطات الدم, الأدوية بحدوث جلطات الدم</p><p><strong>.أثناء تناولكلهذاالدواء،أخبرطبيبكفوراإذاتعرضت لأى مما يلى</strong>:&minus;هذا يمكن أن الشعور بالتوتر و اختلافات في الوعي, تصلب العضلات, ارتفاع فى درجة حرارة الجسم ) حمى (, يكون علامات لما يسمى متلازمة الذهان الخبيثة.&minus;حركات لا إراديةوغيرطبيعيه، وخاصة فياللسانوالفموالفك،مقطباالوجه،ومضات العين السريعةوحركات لايمكنالسيطرةعليهامنالذراعينوالساقينوأصابعاليدينهذه الأعراض قد تكون والقدمين, أعراض خلل الحركة المتأخر.&minus;ثقل اللسان و الأرق و تصلب العضلات. هذه حركات متكرره و الغير عادية لوضعية الجسم , رعاش , لف ,الأعراض قد تكون من أعراض الخارج هرميه</p><p>&nbsp;</p><p>هذا قد يزيد من خطر الإصابة نتيجة حوادث السقوط خاصة عند كبار السن.الدوخة أو شعور النعاس الشديد. &minus;صعوبة في البلع.&minus;قد يحتاج طبيبك إلى مراقبة العلاج عن كثب.زيادة الوزن. &minus; .نوبات الصرع&minus;الانتصابطويلالأمدوالمؤلميمكن أن تكون هذه الحالات ناتجة من هذا النوع من الأدوية و الطبيب قد يحتاج لخفض الجرعة أو إيقاف العلاج.<br /><strong>الأفكار الانتحارية و ازدياد حالة الاكتئاب الخاصة بك</strong></p><p>&nbsp;</p><p>حيث أن هذه الأفكار قد تزيد عند بداية العلاج, قد تراودك بعض أفكار إيذاء النفس أو الانتحار. ًعندما تكون مكتئباهذه الأفكار يمكن أن تزيد إذا أوقفت فجأة تناول أطول. ً أسبوعين ليبدأ مفعولها وأحياناًهذه الأدوية تستغرق عادةدواءك.أظهرت الدراسات السريرية خطورة قد تكون أكثر عرضة لهذه الطريقة فى التفكير إذا كنت من الشباب البالغين. عالية لأفكار الانتحار أو التصرفات الانتحارية في الشباب الأقل فى العمر من 25 و المصابين بالاكتئاب.ً عاما لك عندما تخبر أحد ًقد يكون مفيدا. ًتواصل مع طبيبك أو اذهب للمستشفى فوراإذا راودتك أفكار إيذاء أو قتل نفسك, . يمكن أن تسألهم إذا ما كانوا و اطلب منهم قراءة هذه النشرةًأقاربك أو أحد من أصدقائك المقربين بأنك مكتئباأو أنهم قلقون بشأن بعض التغيرات في تصرفاتك. , ًيعتقدون بأن حالة الاكتئاب الخاصة بك أصبحت أكثر سوء</p><p>&nbsp;</p><p><strong>الأطفال و المراهقين</strong></p><p>لا يستخدم كويتا من قبل المرضى الذين تقل أعمارهم عن 18 لزيادة خطورة الأعراض الجانبية. ً عاما</p><p><strong>ناول أدوية أخرى مع كويتا&nbsp;</strong></p><p>يرجى إخبار الطبيب المعالج أو الصيدلى إذا كنت تتناول أو تناولت في الآونة الأخيرة أو سوف تتناول أي أدوية أخرى. من الأدوية التالية:ً</p><p>لا تتناول كويتا إذا كنت تتناول أيا&minus;بعض أدوية نقص المناعة.&minus;&quot; وهى أدوية لعلاج العدوى الفطرية.&quot;أحد مجموعة أزول&minus;إريثروميسينأومضادات حيوية (.كلاريثروميسين )&minus;نيفازودونلعلاج الاكتئاب (.<strong>) </strong></p><p><strong>من الأدوية التالية:ًأخبر طبيبك المعالج إذا كنت تتناول أيا</strong>&minus;</p><p>)مثل فينيتوين أو كاربامازيبين (.أدوية الصرع &minus;أدوية لعلاج ضغط الدم المرتفع.&minus;الأدوية التي لها فاعلية على الجهاز العصبي المركزي.&minus; )ثيوريدازيندواءلعلاجالاضطرابات .(النفسية&minus;انخفاض في الشوارد )ًعلى سبيل المثال الأدوية التى تسبب خللاالأدوية التي لها تأثير على ضربات القلب, )أدوية لعلاج ( أو بعض المضادات الحيوية حبوب الماءمثل مدرات البول )مستويات البوتاسيوم أو المغنيسيوم ( العدوى (., تحدث مع طبيبك المعالج أو الصيدلى قبل تناول كويتا. من نوع الأدوية التي تتناولهاًإذا لم تكن متأكدا</p><p>ناول كويتا مع الطعام والشراب والكحول يمكنك أن تتناول كويتا مع أو بدون الطعام .حيث أن التأثير المشترك لأقراص كويتا مع الكحول قد يجعلك بشأن كمية الكحول التي تشربها. ًيجب أن تكون حذراتشعر بالنعاس.حيث أن العصير قد يبطل مفعول كويتا.لا تشرب عصير الجريب فروت عند تناولك لأقراص كويتا. الحمل و الرضاعةِيجب عليك أو تخططين للحمل, ًأو تعتقدين أنك قد تكونين حاملا , ً أو تقومين بإرضاع طفلك طبيعياً حاملاِإذا كنتاستشارة طبيبك المعالج أو الصيدلى قبل تناول هذا الدواء.&minus; عدم تناول أقراص كويتا أثناء الحمل إلا بعد استشارة طبيبك المعالج بشأن ذلك.ِيجب عليك&minus;. ً عدم تناول أقراص كويتا فى حالة إرضاعك لطفلك طبيعياِيجب عليكهذه الأعراض يمكن أن تظهر عند الأطفال حديثي الولادة للأمهات اللاتى تناولن كويتيابين خلال الثلاثة أشهر و صعوبة في التغذية. مشاكل في التنفس, أو ضعف , نعاس, هيجان, تيبس العضلات و/ الأخيرة من الحمل: رعشة, إذا أصيب طفلك بأي من هذه الأعراض فقد يلزمك التواصل مع طبيبك المعالج.قيادة السيارات و استخدام الآلاتلذلك لا تقم بالقيادة أو تشغيل الآلات إلا بعد قد تكون هناك خطورة من الشعور بالنعاس عند تناولك لأقراص كويتا. معرفتك لمدى تأثير الأقراص عليك. كويتا يحتوي على اللاكتوزإذا قيل لك من قبل الطبيب أنك مصاب بعدم القدرة على يحتوي كويتا على اللاكتوز و الذي يعتبر نوع من السكر. فاتصل بطبيبك قبل تناولك لهذا المنتج الدوائي.تحمل بعض السكريات, تأثير الدواء على اختبارات البول, فإن تناول كويتا يمكن أن يسبب نتائج إيجابية للميثادون أو أدوية معينة للاكتئاب إذا كان لديك اختبارات تحليل البولتسمى مضادات الاكتئاب ثلاثية الحلقات عندما يتم استخدام بعض طرق الاختبار حتى إذا لم تكن تتناول الميثادون أو . ًقد يتم إجراء بعض الاختبارات الأكثر تخصصافى حالة حدوث ذلك, مضادات الاكتئاب ثلاثية الحلقات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>كيفية تناول كويتا </strong></p><p>.يجب عليك أن تستشير طبيبك المعالج أو الصيدلي إذا كما وصف لك طبيبك المعالج. ً هذا الدواء تماماًتناول دائما. ًكنت غير متأكداالجرعةوالتى تعتمد )الجرعة اليومية ( والجرعة الاستمرارية سوف يقرر طبيبك المعالج بشأن جرعة البداية المناسبة لك. ما تكون بين ًعلى مدى مرضك واحتياجك للعلاج والتى عادة150 ملجم و 800 ملجم. يجب أن تتناول أقراص كويتا الخاصة بك مرة واحدة في اليوم عند النوم أو مرتين على حسب مرضك.<br /><strong>طريقة تناول الأقراص</strong></p><p>&nbsp;</p><p>مع شرب الماء.ًابلع قرص كويتا كامل-&nbsp;يمكنك أن تتناول كويتا مع أو بدون الطعام.&minus;حيث يمكن أن يؤثر على عمل كويتا.لا تشرب عصير الجريب فروت وأنت تتناول كويتا, &minus;لا تتوقف عن تناول أقراص كويتا حتى وإن كنت تشعر بتحسن مالم يطلب منك الطبيب المعالج ذلك.</p><p>مشاكل الكبد, يمكن أن يغير طبيبك المعالج الجرعة الخاصة بك.إذا كانت لديك مشاكل بالكبدالمرضى الكبار في السنإذا كنت من كبار السن يمكن أن يغير طبيبك المعالج الجرعة الخاصة بك.الأطفال و المراهقينلا يستخدم كويتا من قبل المرضى الذين تقل أعمارهم عن 18. ً عاماإذا تناولت أكثر مما يجب من كويتاقد تظهر لديك الأعراض التالية : نعاس, فى حالة تناولك لأقراص كويتا بجرعة أكثر مما وصف لك طبيبك المعالج, خذ معك عليك الاتصال بالطبيب المعالج أو المستشفى على الفور . تسارع فى ضربات القلب. شعور بالدوخة, / أو العبوة حتى يتعرف طبيبك المعالج على الدواء الذى تناولته. نشرة العبوة و الأقراص, إذا نسيت تناول كويتاإلا فى حالة اقتراب موعد الجرعة , تناولها حالما تتذكر. إذا نسيت تناول الجرعة الخاصة بك من أقراص كويتا. لا تقم بمضاعفة الجرعة لتعويض الجرعة المنسية. التالية فيجب عليك الانتظار لحينهاإذا توقفت عن تناول كويتا, مالم يطلب منك طبيبك المعالج ذلك.لا تتوقف عن تناول الأقراص الخاصة بك لأنك تشعر بتحسنأو قد تشعر بإعياء ) غثيان (, أو على النوم ) الأرق (, ًإذا توقفت فجأة عن تناول كويتا يمكن أن تصبح غير قادرا قبل إيقاف ًقد يقترح عليك طبيبك المعالج تقليل الجرعة تدريجيا, دوخة أو هيجان, تشعر بصداع , إسهال , تقيؤالعلاج.فأسأل طبيبك المعالج أو الصيدلي.إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء,&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>وإن لم تكن تحدث لكل من يتناول هذا الدواء. جانبيةًقد يسبب كويتا أعراضامثل جميع الأدوية, إذا تعرضت لأي من الأعراض التالية توقف عن تناول كويتا و اتصل بطبيبك المعالج أو اذهب لأقرب مستشفى فقد تحتاج إلى عناية طبية عاجلة.على الفور, قد تؤثر على ما يصل إلى الأعراض الجانبية الغير شائعة )1 من 100 شخص(&minus;و تورم في الجلد و تورم حول الفم.)الشرى (, تفاعلات الحساسية التي تشمل كتل مرتفعة عن سطح الجلد &minus;نوبات الصرع</p><p>&minus;وأصابع , والساقين, في الذراعينً, وأيضا ما تكون في اللسان والفم والفكًحركات لا يمكنك التحكم فيها , غالباهذه الأعراض قد تكون أعراض حالة تسمى &quot; خلل . تقطيب الوجه و تسارع ومضات العين. اليدين والقدمينالحركة المتأخر&quot;.</p><p>&nbsp;</p><p><strong>.قد تؤثر على ما يصل إلى الأعراض الجانبية النادرة )1 من 1000 شخص(</strong></p><p>&minus;ارتفاع شديد , أو إغماء, , والنعاس الشديدوتيبس العضلاتوالتعرق, حالة من ارتفاع درجة الحرارة ) حمى (, اضطراب يسمى متلازمة الذهان الخبيثة (.في ضغط الدم و تسارع فى ضربات القلب )&minus;اصفرار الجلد و العينين ) اليرقان (.&minus;التهاب كبدى(التهاب فى الكبد )&minus;الانتصام الدائم المؤلم طويل المدى.&minus;و تشمل الأعراض تورم و ألم و احمرار في الساق والتي في الساقين , )ًجلطات الدم في الأوردة و خصوصاقدتنتقلعبرالأوعيةالدمويةإلىالرئتينممايسببألمفيالصدروصعوبةفي .(التنفس&minus;التهاب البنكرياس. ويمكنأنتشملالأعراضآلامحادةفيالبطنوالظهر،والغثيان و القيء</p><p>&nbsp;</p><p><strong>.قد تؤثر على ما يصل إلى ) ًالأعراض الجانبية النادرة جدا1 من 10,000 شخص(</strong></p><p>&minus;ردالفعلالتحسسيالشديد) ويسمىالحساسيةالمفرطة (والتيقدتسببصعوبةفيالتنفسأو .صدمة&minus;تورمسريعفىالجلد،ًوعادةمايكون حولالعينينوالشفتينوالحلق )وذمة .(وعائية&minus;طفحجلديشديد،وظهوربثورأو بقع حمراءعلى, متلازمة ستيفن جونسون.الجلد&minus;تحلل غير طبيعى فى العضلات ) انحلالوضعف وتورم العضلات بأعراض مثل ألم, ً( مصحوباالربيداتتحول لون البول إلى اللون القاتم (.والذى قد يؤدى إلى مشاكل بالكلى )</p><p><strong>معدل تكرار حدوثها لا يستدل عليه من البيانات المتاحة (:الأعراض الجانبية الغير معروفة )</strong></p><p>&minus;أمراض جلدية حادة والتي تسمى انحلال البشرة السمي ) الطفحالجلديالشديدبمافيذلكاحمرار،تقشيروتورمفيالجلديشبهحروقوحماميشديدة ( متعددةالأشكال )بقع حمراءغيرمنتظمةعلىالجلدفياليدينوالذراعين (</p><p><strong>.أعراض جانبية أخرى محتملة:ًشائعة جداقد تؤثر في أكثر من ) 1 من 10 أشخاص (:</strong></p><p>&minus;صداع و جفاف الفم.دوخة )والتي قد تؤدي إلى السقوط (, &minus; فى تناول أقراصك(ًهذا الشعور يمكن أن يختفي مع الوقت مادمت منتظماشعور بالنعاس ) &minus;و التي تتضمن عدم الأعراض التي تحدث عندما تتوقف عن تناول كويتا ( أعراض التوقف عن تناول الدواء ), الدوخة و الهيجان.الإسهال, القيء, الصداع, المقدرة على النوم ) الأرق (, الغثيان&minus;)الدهون الثلاثية و الكوليستيرول ( في الدم.تغيرات في كميات بعض الدهون &minus; .زيادة الوزن&minus;الهيموجلوبين (.انخفاض مستويات البروتين في كريات الدم الحمراء )شائعة )قد تؤثر في 1 من 10 أشخاص(&minus;انخفاض في عدد كريات الدم البيضاء.&minus;قد يؤدي إلى السقوط(إغماء )&nbsp;</p><p>&minus;تسارع ضربات القلب.&minus;الإحساس بضربات القلب الغير عادية ) الخفقان(&minus;بحة في الصوت(ضيق في التنفس )&minus;انخفاض في ضغط الدم خاصة عند الوقوف و الذي ينتج عنه الشعور بالدوخة و الإغماء الذي يؤدي إلى السقوط.&minus; .انسداد الأنف&minus;عسر هضم وتقيؤ.إمساك, &minus;أعراضجانبيةخارجالهرمية مع أعراض. مما يشملمثل حركات العضلات الغير طبيعية و المتكررةصعوبةفى بداية حركةالعضلات،ارتعاش،وشعوربعدم الراحة أوتيبسالعضلاتمندون .ألم&minus;أحلام غير عادية و كوابيس.&minus;أفكارانتحاريةوتفاقمالاكتئابالخاص .بك&minus; .زيادة الشهية&minus;اضطراب في الكلام و اللغة.&minus;زيادةفيكميةهرمونالبرولاكتينفيالدم . فيحالاتنادرةيمكنأنيؤديإلىتورمالثديين وإفراز اللبن من إلى انقطاع أو عدم انتظام الدورة الشهرية ً. وقد يؤدي أيضاالثدى بشكل غير متوقع عند الرجال والنساءعند النساء.)الطمث ( &minus;عدم وضوح الرؤية.&minus;الشعور بالغضب.&minus; .الحمى&minus;)العدلات أو انخفاض أو ارتفاع في خلايا الدم البيضاء تغيرات ملاحظة في تحاليل الدم كارتفاع إنزيمات الكبد, (, تغيرات في الهرمونات الدرقية )الحمضات على الترتيبT4 الكامل , T4 الحر, T3 الكامل, TSHو زيادة ()الجلوكوز (.في سكر الدم &minus; .شعور بالتعب&minus;تورم الساقين أو الذراعين.</p><p><strong>قد تؤثر في غير شائعة )1 من 100 شخص(</strong></p><p>&minus;شعور غير مريح في الساقين (.متلازمة تملل الساقين )&minus;صعوبة في البلع.&minus;حالة القلب التي تسمى إطالة الفترة الزمنية QTتقاس بواسطة و التي يمكن أن تؤثر على إيقاع ضربات القلب )رسم القلب الكهربائى(&minus;مرضالسكريأوتفاقممرضالسكريالموجودمن .قبل&minus; .العجز الجنسي&minus;التغيرات الملحوظة في تحاليل الدم كزيادة في بعض الإنزيمات مثل غاما GTانخفاض في عدد كريات الدم , أو انخفاض مستويات الصوديوم في الدم نقص الصفيحات ( ( أو الصفائح الدموية في الدم )الحمراء )الأنيميا( أو التغيراتنقص صوديوم الدم)فيكميةهرموناتالغدةالدرقية T3 انخفاض , ومشاكل الغدة الدرقية )الحرهرمونات الغدة الدرقية (.&minus;تباطؤ نبضات القلب.</p><p><strong>قد تؤثر في نادرة )1 من 1000 شخص(</strong></p><p>&minus;تورمالثديينوإفرازغيرمتوقعلحليب .الثدي</p><p>&nbsp;</p><p>اضطرابات الحيض.&minus;متلازمةالأيض) تغيراتفيوزن الجسم، ومستوىالسكروبعضالدهونفيالدموالتييمكنأنتزيدمنخطرالتعرضلمشاكلالقلبومرض (السكري&minus;وخلل بالأكل متعلق بالنوم. , والكلام أثناء النوم, المشي أثناء النوم&minus;انخفاض درجة حرارة الجسم.&minus;زيادةمستوياتإنزيمالكرياتينانخفاضفسفوكيناز, فيبعضأنواعخلاياالدمالبيضاء) ندرةالمحببات (كمايتضحفياختبارات .<br />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>قد تؤثر في ) ًنادرة جدا1 من 10.000 شخص (</strong></p><p>&minus;والتى تسبب نقص مستوى حالة تسمى &quot;متلازمة إفراز الهرمون المضاد لإفراز البول بصورة غير مناسبة&quot; , والضعف. والارتباك مثل الصداع, الغثيان, ً. مما قد يسبب أعراضاالصوديوم فى الدممعدل تكرار حدوثها لا يمكن الاستدلال عليه من البيانات المتاحة (:غير معروفة )&minus;نقص العدلات(انخفاض عدد كريات الدم البيضاء )فصيلة الأدوية التي ينتمي إليها كويتا قد تسبب مشاكل في إيقاع ضربات القلب,والتييمكنأنتكونخطيرةوفيالحالاتالشديدةقدتكون .قاتلةأعراض جانبية إضافية تظهر عند الأطفال و المراهقينالأعراض الجانبية , يمكن أن تظهر عند الأطفال و المراهقين. نفس الأعراض الجانبية التي قد تظهر عند الكبارالتالية تم رصدها عند الأطفال و المراهقين أكثر منها عند الكبار أو تم رصدها فقط عند الأطفال و المراهقين:</p><p><strong>قد تؤثر في ) ًشائعة جدا1 من 10 أشخاص(</strong></p><p>&minus;ارتفاع في ضغط الدم.&minus;ارتفاع هذا الهرمون قد يؤدي في حالات نادرة إلى:ارتفاع في معدل هرمون البرولاكتين في الدم, &bull;و إفراز غير متوقع للحليب من الثدى.انتفاخ في الثديين عند الأولاد و البنات, &bull;انقطاع الطمث أو عدم انتظام الدورة الشهرية عند البنات.&minus; .زيادة الشهية&minus;الأعراضالجانبيةخارجالهرمية مع أعراض. مما يشمل مثل حركات العضلات الغير طبيعية و المتكررةصعوبة فى بداية حركة العضلات،وارتعاش،وشعوربعدم الراحة أوتيبسالعضلاتبدون .ألم</p><p><strong>قد تؤثر في شائعة )1 من 10 أشخاص (:</strong></p><p>&minus;الشعور بالغضببما فى ذلك أى أعراض جانبية لم يتم تواصل مع طبيبك المعالج أو الصيدلى. إذا تعرضت لأى أعراض جانبية, ذكرها فى هذه النشرة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>عن متناول ونظر الأطفال.ًاحفظ هذا الدواء بعيدا يحفظفيدرجةحرارةأقلمن30درجةمئوية</p><p>لا تستخدم كويتا بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط بعد كلمة &quot;EXP&quot; بأن تاريخ ً. علماالصلاحية يشير إلى آخر يوم فى الشهر المذكور.لا يتطلب هذا الدواء أي ظروف تخزين خاصة.. اسأل الصيدلي حول لا ينبغى أن يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية و سوف تساعد هذه التدابير على حماية البيئة.كيفية التخلص من الأدوية التي لم تعد مطلوبة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>&minus;كل قرص مغلف بطبقة رقيقة من كويتا يحتوي على المادة الفعالة هي كويتيابين . 25 ملجم, 100 ملجم , 150ملجم , 200 ملجم أو 300 ملجم من المادة الفعالة.&minus;المكونات الأخرى هي :لب القرص:بوفيدون سيليولوز دقيق التبلور, K 29-32جليكولات هيدروجين كالسيوم فوسفات ثنائي التميه, ,ستيارات مغنيسيوم. (, لاكتوز أحادى التميه, صوديوم النشا ) نوع أغلاف القرص: هيبروميللوز 6Cp (E464), ثانى أكسيد التيتانيوم )E171, ماكروجول (, لاكتوز أحادى التميه3350, أكسيد حديد أصفر ), تراي أسيتينE172( )فى أقراص كويتا 25 ملجم, 100 ملجم , و150 ملجم (, أكسيد حديد أحمر )E172( )فقط فى أقراص كويتا 25 ملجم (.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>كويتا 25 ملجم هى أقراص دائرية الشكل مغلفة بطبقة رقيقة, قطرها 5.5لونها برتقالي فاتح , , ثنائية التحدب, ملممحفور عليها حرف Q من جانب واحد. كويتا 100 ملجم هى أقراص دائرية الشكل مغلفة بطبقة رقيقة, قطرها 8.5محفور لونها أصفر, , ثنائية التحدب, ملمعليها حرف Q من جانب واحد. كويتا 150 ملجم هى أقراص مغلفة بطبقة رقيقة بيضاوية الشكل بأبعاد 6.9 ملم X13.8, ثنائية التحدب, لونها ملم, محفور عليها حرف أصفر فاتح Q من جانب واحد. كويتا 200 ملجم هى أقراص مغلفة بطبقة رقيقة بيضاوية الشكل بأبعاد 16 ملم X8.2, ثنائية التحدب, لونها ملم, محفور عليها حرف أبيض Q من جانب واحد. الكويتا 300أبعادها ملجم أقراص مغلفة بطبقة رقيقة بيضاوية الشكل , 19 ملم, &times;7.6 ملم ثنائية التحدب, لونها , محفور عليها حرف أبيضQ من جانب واحد ورقم 300 من الجانب الآخر. أحجام العبوة: الشرائط: كويتا 25تحتوى العبوة على ملجم أقراص مغلفة بطبقة رقيقة: 6 ,10 ,20 ,30 ,50 ,60 ,90, أو 100 قرص. كويتا 100تحتوى العبوة على ملجم أقراص مغلفة بطبقة رقيقة: 6 ,10 ,20 ,30 ,50 ,60 ,90, أو 100 قرص. كويتا 150تحتوى العبوة على ملجم أقراص مغلفة بطبقة رقيقة: 6 ,10 ,20 ,30 ,50 ,60 ,90, أو 100 قرص. كويتا 200تحتوى العبوة على ملجم أقراص مغلفة بطبقة رقيقة: 6 ,10 ,20 ,30 ,50 ,60 ,90, أو 100 قرص. كويتا 300تحتوى العبوة على ملجم أقراص مغلفة بطبقة رقيقة: 6 ,10 ,20 ,30 ,50 ,60 ,90, أو 100 قرص.</p><p>&nbsp;</p><p>حاويات الأقراص: كويتا 25تحتوى الحاوية على ملجم أقراص مغلفة بطبقة رقيقة: 100 أو 250 قرص. كويتا 100تحتوى الحاوية على ملجم أقراص مغلفة بطبقة رقيقة: 100 أو 250 قرص.كويتا 150تحتوى الحاوية على ملجم أقراص مغلفة بطبقة رقيقة: 100 أو 250 قرص.كويتا 200تحتوى الحاوية على ملجم أقراص مغلفة بطبقة رقيقة: 100 أو 250 قرص.كويتا 300تحتوى الحاوية على ملجم أقراص مغلفة بطبقة رقيقة: 60 أو 100 أو 250 قرص.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>الشركةالمصنعةوصاحبالحقوقالتسويقيةصنعبواسطةأكتافيس،ما لطا لصالح: الدوائيةمصنعالأدويةبالقصيمالشركةالسعوديةللصناعاتالدوائيةوالمستلزماتالطبيةالمملكةالعربية السعوديه<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Qatpen 25 mg film-coated tablets 
Qatpen 100 mg film-coated tablets 
Qatpen 150 mg film-coated tablets 
Qatpen 200 mg film-coated tablets 
Qatpen 300 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Qatpen tablet 25 mg contains 25 mg quetiapine (as fumarate).  
Excipient with known effect: 
Lactose monohydrate corresponding to 4.9 mg lactose anhydrous.
 
 
Each Qatpen tablet 100 mg contains 100 mg quetiapine (as fumarate). 
 
Excipient with known 
 
 
Lactose monohydrate corresponding to 19.7 mg lactose anhydrous. 
 
Each Qatpen  tablet 150 mg contains 150 mg quetiapine 
  
 
Excipient with known 
 
 
Lactose monohydrate corresponding to 29.5 mg lactose 
 
 
Each Qatpen tablet 200 mg contains 200 mg quetiapine 
  
 
Excipient with known 
 
 
Lactose monohydrate corresponding to 39.3 mg lactose 
 
 
Each Qatpen tablet 300 mg contains 300 mg quetiapine 
  
 
Excipient with known 
 
 
Lactose monohydrate corresponding to 59 mg lactose 
 
 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. 
 
Qatpen 25mg FCT - Light orange to orange color, round, biconvex, film-coated tablet, 
embossed with "T61"on one side and plain on the other side. 
 
Qatpen 100mg FCT - Light yellow to yellow, round biconvex, film-coated tablet, embossed 
with "T62" on one side and plain on the other side. 
 
Qatpen 150mg FCT - Pale yellow, oval, biconvex, film-coated tablet, embossed with "T72" 
on one side and plain on the other side. 
 
Qatpen 200mg FCT - White to off-white, oval, biconvex, film-coated tablet, embossed with 
"T73" on one side and plain on the other side. 
 
Qatpen 300mg FCT - White to off-white, oval, biconvex, film-coated tablet, embossed with 
"T74" on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- &nbsp; &nbsp; &nbsp; &nbsp;Qatpen is indicated for the treatment of schizophrenia.&nbsp;<br />- &nbsp; &nbsp; &nbsp; &nbsp;Qatpen is indicated for treatment of bipolar disorder:&nbsp;<br />-for the treatment of moderate to severe manic episodes in bipolar disorder&nbsp;<br />-for the treatment of major depressive episodes in bipolar disorder&nbsp;<br />-for the prevention of recurrence in patients with bipolar disorder, in patients whose&nbsp;<br />manic or depressive episode has responded to quetiapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />&nbsp;<br />&nbsp;<br />Different dosing schedules exist for each indication. It must therefore be ensured that patients&nbsp;<br />receive clear information on the appropriate dosage for their condition.&nbsp;<br />&nbsp;<br /><em>Adults&nbsp;<br /><u>For the treatment of schizophrenia&nbsp;</u></em><br />Qatpen should be administered twice a day. The total daily dose for the first four days of&nbsp;<br />therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4).&nbsp;<br />&nbsp;<br />From Day 4 onwards, the dose should be titrated to the usual effective dose range of 300 to&nbsp;<br />450 mg/day. Depending on the clinical response and tolerability of the individual patient, the&nbsp;<br />dose may be adjusted within the range 150 to 750 mg/day.</p><p><em><u>For the treatment of moderate to severe manic episodes associated with bipolar disorder&nbsp;</u></em><br />Qatpen should be administered twice a day. The total daily dose for the first four days of&nbsp;<br />therapy is 100 mg (Day 1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4). Further&nbsp;<br />dosage adjustments up to 800 mg/day by Day 6 should be in increments of no greater than 200&nbsp;<br />mg per day.&nbsp;<br />&nbsp;<br />The dose may be adjusted depending on clinical response and tolerability of the individual&nbsp;<br />patient, within the range of 200 to 800 mg per day. The usual effective dose is in the range of&nbsp;<br />400 to 800 mg per day.&nbsp;<br />&nbsp;<br /><u><em>For the treatment of depressive episodes in bipolar disorder&nbsp;</em></u><br />Qatpen should be administered once daily at bedtime. The total daily dose for the first four&nbsp;<br />days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4). The&nbsp;<br />recommended daily dose is 300 mg.&nbsp;<br />&nbsp;<br />In clinical trials, no additional benefit was seen in the 600 mg group compared to the 300 mg&nbsp;<br />group (see section 5.1). Individual patients may benefit from a 600 mg dose. Doses greater&nbsp;<br />than 300 mg should be initiated by physicians experienced in treating bipolar disorder. In&nbsp;<br />individual patients, in the event of tolerance concerns, clinical tria<br />ls have indicated that dose&nbsp;<br />reduction to a minimum of 200 mg could be considered.&nbsp;<br />&nbsp;<br /><u><em>For preventing recurrence in bipolar disorder</em></u><br />&nbsp;<br />For preventing recurrence of manic, mixed or depressive episodes in bipolar disorder, patients&nbsp;<br />who have responded to quetiapine for acute treatment of bipolar disorder should continue&nbsp;<br />therapy at the same dose. The dose may be adjusted depending on clinical response and&nbsp;<br />tolerability of the individual patient, within the range of 300 to 800 mg/day administered&nbsp;<br />twice daily. It is important that the lowest effective dose is used for maintenance therapy.&nbsp;<br />&nbsp;<br /><em>Elderly</em>&nbsp;<br />As with other antipsychotics and antidepressants, quetiapine should be used with caution in&nbsp;<br />the elderly, especially during the initial dosing period. The rate of dose titration of quetiapine&nbsp;<br />may need to be slower, and the daily therapeutic dose lower, than that used in younger&nbsp;<br />patients, depending on the clinical response and tolerability of the individual patient. The&nbsp;<br />mean plasma clearance of quetiapine was reduced by 30% to 50% in elderly patients when&nbsp;<br />compared to younger patients.&nbsp;<br />&nbsp;<br />Efficacy and safety have not been evaluated in patients over 65 years with depressive episodes&nbsp;<br />in the framework of bipolar disorder.&nbsp;<br />&nbsp;<br /><em>Paediatric population&nbsp;</em><br />Qatpen is not recommended for use in children and adolescents below 18 years of age, due to&nbsp;<br />a lack of data to support use in this age group. The available evidence from placebo-controlled&nbsp;<br />clinical trials with quetiapine is presented in sections 4.4, 4.8, 5.1 and 5.2.&nbsp;<br />&nbsp;<br /><em>Renal impairment&nbsp;</em><br />Dosage adjustment is not necessary in patients with renal impairment.<br />&nbsp;<br /><em>Hepatic impairment&nbsp;</em><br />Quetiapine is extensively metabolised by the liver. Therefore, quetiapine should be used with&nbsp;<br />caution in patients with known hepatic impairment, especially during the initial dosing period.&nbsp;<br />&nbsp;<br />Patients with hepatic impairment should be started with 25 mg/day. The dose can be increased&nbsp;<br />in increments of 25 - 50 mg/day to an effective dose, depending on the clinical response and&nbsp;<br />tolerability of the individual patient.&nbsp;<br />&nbsp;<br /><u>Method of administration</u><br />&nbsp;<br />Qatpen can be administered with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Concomitant administration of cytochrome P450 3A4 inhibitors such as HIV-protease 
inhibitors, 
azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is 
contraindicated (see
 section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As quetiapine has several indications, the safety profile should be considered with respect to&nbsp;<br />the individual patients diagnosis<br />&nbsp;and the dose being administered.&nbsp;<br />&nbsp;<br /><u>Paediatric population &nbsp;(10 to 17 years of age):&nbsp;</u><br />Qatpen is not recommended for use in children and adolescents below 18 years of age, due to&nbsp;<br />a lack of data to support use in this age group. Clinical trials with quetiapine have shown that&nbsp;<br />in addition to the known safety profile identified in adults (see section 4.8), certain adverse&nbsp;<br />events occurred at a higher frequency in children and adolescents compared to adults&nbsp;<br />(increased appetite, elevations in serum prolactin, and extrapyramidal symptoms) and one was&nbsp;<br />identified that has not been previously seen in adult studies (increases in blood pressure).&nbsp;<br />Changes in thyroid function tests have also been observed in children and adolescents.&nbsp;<br />&nbsp;<br />Furthermore, the long-term safety implications of treatment with quetiapine on growth and&nbsp;<br />maturation have not been studied beyond 26 weeks. Long-term implications for cognitive and&nbsp;<br />behavioural development are not known.&nbsp;<br />&nbsp;<br />In placebo-controlled clinical trials with children and adolescent patients treated with&nbsp;<br />quetiapine, quetiapine was associated with an increased incidence of extrapyramidal&nbsp;<br />symptoms (EPS) compared to placebo in patients treate<br />d for schizophrenia and bipolar mania&nbsp;<br />(see section 4.8).&nbsp;<br />&nbsp;<br /><u>Suicide/suicidal thoughts or clinical worsening:&nbsp;</u><br />Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide&nbsp;<br />(suicide- related events). This risk persists until significant remission occurs. As improvement</p><p>may not occur during the first few weeks or more of treatment, patients should be closely&nbsp;<br />monitored until such improvement occurs. It is general clinical experience that the risk of&nbsp;<br />suicide may increase in the early stages of recovery.&nbsp;<br />&nbsp;<br />In addition, physicians should consider the potential risk of suicide-related events after abrupt&nbsp;<br />cessation of quetiapine treatment, due to the known risk factors for the disease being treated.&nbsp;<br />Other psychiatric conditions for which quetiapine is prescribed, can also be associated with an&nbsp;<br />increased&nbsp;<br />risk of suicide related events. In addition, these conditions may be co-morbid with&nbsp;<br />major depressive episodes. The same precautions observed when treating patients with major&nbsp;<br />depressive episodes should therefore be observed when treating patients with other psychiatric&nbsp;<br />disorders.&nbsp;<br />&nbsp;<br />Patients with a history of suicide related events, or those exhibiting a significant degree of&nbsp;<br />suicidal ideation prior to commencement of treatment are known to be at greater risk of&nbsp;<br />suicidal thoughts or suicide attempts, and should receive car<br />eful monitoring during treatment.&nbsp;<br />A meta analysis of placebo controlled clinical trials of antidepressant drugs in adult patients&nbsp;<br />with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants&nbsp;<br />compared to placebo in patients less than 25 years old.&nbsp;<br />&nbsp;<br />Close supervision of patients and in particular those at high risk should accompany drug&nbsp;<br />therapy especially in early treatment and following dose changes. Patients (and caregivers of&nbsp;<br />patients) should be alerted about the need to monitor for any clinical worsening, suicidal&nbsp;<br />behaviour or thoughts and unusual changes in behaviour and to seek medical advice&nbsp;<br />immediately if these symptoms present.&nbsp;<br />&nbsp;<br />In shorter-term placebo controlled clinical studies of patients with major depressive episodes&nbsp;<br />in bipolar disorder an increased risk of suicide-related events was observed in young adults&nbsp;<br />patients (younger than 25 years of age) who were treated with quetiapine as compared to those&nbsp;<br />treated with placebo (3.0% vs. 0%, respectively).&nbsp;<br />&nbsp;<br /><u>Extrapyramidal symptoms:&nbsp;</u><br />In placebo controlled clinical trials of adult patients quetiapine was associated with an&nbsp;<br />increased incident of extrapyramidal symptoms (EPS) compared to placebo in patients treated&nbsp;<br />for major depressive episodes in bipolar disorder (see sections 4.8 and 5.1).&nbsp;<br />&nbsp;<br />The use of quetiapine has been associated with the development of akathisia, characterised by&nbsp;<br />a subjectively unpleasant or distressing restlessness and need to move often accompanied by&nbsp;<br />an inability to sit or stand still. This is most likely to occur within the first few weeks of&nbsp;<br />treatment. In patients who develop these symptoms, increasing the dose may be detrimental.&nbsp;<br />&nbsp;<br /><u>Tardive dyskinesia:&nbsp;</u><br />If signs and symptoms of tardive dyskinesia appear, dose reduction or discontinuation of&nbsp;<br />quetiapine should be considered. The symptoms of tardive dyskinesia can worsen or even&nbsp;<br />arise after discontinuation of treatment (see section 4.8).</p><p><u>Somnolence and dizziness:&nbsp;</u><br />Quetiapine treatment has been associated with somnolence and related symptoms, such as&nbsp;<br />sedation (see section 4.8). In clinical trials for treatment of patients with bipolar depression,&nbsp;<br />onset was usually within the first 3 days of treatment and was predominantly of mild to&nbsp;<br />moderate intensity. Bipolar depression patients experiencing somnolence of severe intensity&nbsp;<br />may require more frequent contact for a minimum of 2 weeks from onset of somnolence, or&nbsp;<br />until symptoms improve and treatment discontinuation may need to be conside<br />red.&nbsp;<br />&nbsp;<br />Quetiapine treatment has been associated with orthostatic hypotension and related dizziness&nbsp;<br />(see section 4.8) which, like somnolence has onset usually during the initial dose-titration&nbsp;<br />period. This could increase the occurrence of accidental injury (fall), especially in the elderly&nbsp;<br />population. Therefore, patients should be advised to exercise caution until they are familiar&nbsp;<br />with the potential effects of the medication.&nbsp;<br />&nbsp;<br /><u>Cardiovascular:</u><br />&nbsp;<br />Quetiapine should be used with caution in patients with known cardiovascular disease,&nbsp;<br />cerebrovascular disease, or other conditions predisposing to hypotension.&nbsp;<br />Quetiapine may induce orthostatic hypotension, especially during the initial dose-titration&nbsp;<br />period and therefore dose reduction or more gradual titration should be considered if this&nbsp;<br />occurs. A slower titration regimen could be considered in patients with underlying&nbsp;<br />cardiovascular disease.&nbsp;<br />&nbsp;<br /><u>Seizures:&nbsp;</u><br />In controlled clinical trials there was no difference in the incidence of seizures in patients&nbsp;<br />treated with quetiapine or placebo. No data is available about the incidence of seizures in&nbsp;<br />patients with a history of seizure disorder. As with other antipsychotics, caution is&nbsp;<br />recommended when treating patients with a history of seizures (see section 4.8).&nbsp;<br />&nbsp;<br /><u>Neuroleptic malignant syndrome:&nbsp;</u><br />Neuroleptic malignant syndrome has been associated with antipsychotic treatment, including&nbsp;<br />quetiapine (see section 4.8). Clinical manifestations include hyperthermia, altered mental&nbsp;<br />status, muscular rigidity, autonomic instability, and increased creatine phosphokinase. In such&nbsp;<br />an event, quetiapine should be discontinued and appropriate medical treatment given.&nbsp;<br />&nbsp;<br /><u>Severe neutropenia:</u><br />&nbsp;<br />Severe neutropenia (neutrophil count &lt;0.5 X 10<br />9<br />/L) has been uncommonly reported in&nbsp;<br />quetiapine clinical trials. Most cases of severe neutropenia have occurred within a couple of&nbsp;<br />months of starting therapy with quetiapine. There was no apparent dose relationship. During&nbsp;<br />post-marketing experience, resolution of leucopenia and/or neutropenia has followed&nbsp;<br />cessation of therapy with quetiapine. Possible risk factors for neutropenia include pre-existing&nbsp;<br />low white cell count (WBC) and history of drug induced neutropenia. &nbsp;<br />&nbsp;<br />Quetiapine should be discontinued in patients with a neutrophil count &lt;1.0 X 10<br />9<br />/L. Patients&nbsp;<br />should be observed for signs and symptoms of infection and neutrophil counts followed (until&nbsp;<br />they exceed 1.5 X 10<br />9<br />/L). (See section 5.1).</p><p><u>Interactions:</u><br />&nbsp;<br />See also section 4.5.&nbsp;<br />&nbsp;<br />Concomitant use of quetiapine with a strong hepatic enzyme inducer such as carbamazepine&nbsp;<br />or phenytoin substantially decreases quetiapine plasma concentrations, which could affect the&nbsp;<br />efficacy of quetiapine therapy. In patients receiving a hepatic enzyme inducer, initiation of&nbsp;<br />quetiapine should only occur if the physician considers that the benefits of quetiapine&nbsp;<br />outweigh the risks of removing the hepatic enzyme inducer. It is important that any change in&nbsp;<br />the inducer is gradual, and if required, replaced with a non-i<br />nducer (e.g. sodium valproate).&nbsp;<br />&nbsp;<br /><u>Weight:</u><br />&nbsp;<br />Weight gain has been reported in patients who have been treated with quetiapine, and should&nbsp;<br />be monitored and managed as clinically appropriate as in accordance with utilized&nbsp;<br />antipsychotic guidelines (see sections 4.8 and 5.1).&nbsp;<br />&nbsp;<br /><u>Hyperglycaemia:</u><br />&nbsp;<br />Hyperglycaemia and/ or development or exacerbation of diabetes occasionally associated with&nbsp;<br />ketoacidosis or coma has been reported rarely, including some fatal cases (see section 4.8). In&nbsp;<br />some cases, a prior increase in body weight has been reported which may be a predisposing&nbsp;<br />factor. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic&nbsp;<br />guidelines. Patients treated with any antipsychotic agent including quetiapine, should be&nbsp;<br />observed for signs and symptoms of hyperglycaemia, (such as polydipsia, polyuria,&nbsp;<br />polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes&nbsp;<br />mellitus should be monitored regularly for worsening of glucose control. Weight should be&nbsp;<br />monitored regularly.&nbsp;<br />&nbsp;<br /><u>Lipids:&nbsp;</u><br />Increases in triglycerides, LDL- and total cholesterol, and decreases in HDL cholesterol have&nbsp;<br />been observed in clinical trials with quetiapine (see section 4.8). Lipid changes should be&nbsp;<br />managed as clinically appropriate.&nbsp;<br />&nbsp;<br /><u>Metabolic risk:&nbsp;</u><br />Given the observed changes in weight, blood glucose (see hyperglycaemia) and lipids seen in&nbsp;<br />clinical studies, patients (including those with normal baseline values) may experience&nbsp;<br />worsening of their metabolic risk profile, which should be managed as clinically appropriate&nbsp;<br />(see also section 4.8).&nbsp;<br />&nbsp;<br /><u>QT prolongation:&nbsp;</u><br />In clinical trials and use in accordance with the Summary of Product Characteristics,&nbsp;<br />quetiapine was not associated with a persistent increase in absolute QT intervals. In post-<br />marketing, QT prolongation was reported with quetiapine at the therapeutic doses (see section&nbsp;<br />4.8) and in overdose (see section 4.9). As with other antipsychotics, caution should be&nbsp;<br />exercised when quetiapine is prescribed in patients with cardiovascular disease or family&nbsp;<br />history of QT prolongation. Also, caution should be exercised when quetiapine is prescribed&nbsp;<br />either with medicines known to increase QT interval, or with concomitant neuroleptics,</p><p>especially in the elderly, in patients with congenital long QT syndrome, congestive heart<br />failure, heart hypertrophy, hypokalaemia or hypomagnesaemia (see section 4.5).<br />&nbsp;</p><p><u>Withdrawal:</u><br />Acute withdrawal symptoms such as insomnia, nausea, headache, diarrhoea, vomiting,<br />dizziness and irritability have been described after abrupt cessation of quetiapine. Gradual<br />withdrawal over a period of at least one to two weeks is advisable (see section 4.8).<br />&nbsp;</p><p><u>Elderly patients with dementia-related psychosis:</u><br />Quetiapine is not approved for the treatment of dementia-related psychosis.<br />An approximately 3-fold increased risk of cerebrovascular adverse events has been seen in<br />randomised placebo-controlled trials in the dementia population with some atypical<br />antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot<br />be excluded for other antipsychotics or other patient populations. Quetiapine should be used<br />with caution in patients with risk factors for stroke.<br />In a meta-analysis of atypical antipsychotics it has been reported that elderly patients with<br />dementia- related psychosis are at an increased risk of death compared to placebo. However,<br />in two 10-week placebo-controlled quetiapine studies in the same patient population (n=710;<br />mean age 83 years; range: 56-99 years) the incidence of mortality in quetiapine treated<br />patients was 5.5% versus 3.2% in the placebo group. The patients in these trials died from a<br />variety of causes that were consistent with expectations for this population. These data do not<br />establish causal relationship between quetiapine treatment and death in elderly patients with<br />dementia.<br />&nbsp;</p><p><u>Dysphagia:</u><br />Dysphagia (see section 4.8) has been reported with quetiapine. Quetiapine should be used<br />with caution in patients at risk for aspiration pneumonia.</p><p><u>Venous thromboembolism (VTE):</u><br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since<br />patients treated with antipsychotics often present with acquired risk factors for VTE, all<br />possible risk factors for VTE should be identified before and during treatment with quetiapine<br />and preventive measures undertaken.</p><p><u>Pancreatitis:</u><br />Pancreatitis has been reported in clinical trials and during the post marketing experience.<br />Among the post marketing reports, while not all cases were confounded by risk factors, many<br />patients had factors which are known to be associated with pancreatitis such as increased<br />triglycerides (see section 4.4 Lipids), gallstones, and alcohol consumption.</p><p><u>Additional information:</u><br />Quetiapine data in combination with divalproex or lithium in acute moderate to severe manic<br />episodes is limited; however, combination therapy was well tolerated (see section 4.8 and<br />5.1). The data showed an additive effect at week 3.</p><p><u>Lactose:</u><br />Qatpen contains lactose monohydrate. Patients with rare hereditary problems of galactose&nbsp;<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take&nbsp;<br />this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the primary central nervous system effects, quetiapine should be used with caution in&nbsp;<br />combination with other centrally acting medicinal products and alcohol.&nbsp;<br />&nbsp;<br />Cytochrome P450 (CYP) 3A4 is the enzyme that is primarily responsible for the cytochrome&nbsp;<br />P450&nbsp;<br />mediated metabolism of quetiapine. In an interaction study in healthy volunteers,&nbsp;<br />concomitant administration of quetiapine (dosage of 25 mg) with ketoconazole, a CYP3A4&nbsp;<br />inhibitor, caused a 5- to 8-fold increase in the AUC of quetiapine. On the basis of this,&nbsp;<br />concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated. It is also not&nbsp;<br />recommended to consume grapefruit juice while on quetiapine therapy.&nbsp;<br />&nbsp;<br />In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine given before&nbsp;<br />and during treatment with carbamazepine (a known hepatic enzyme inducer), co-<br />administration of carbamazepine significantly increased the clearance of quetiapine. This&nbsp;<br />increase in clearance reduced systemic quetiapine exposure (as measured by AUC) to an&nbsp;<br />average of 13% of the exposure during administration of quetiapine alone; although a greater&nbsp;<br />effect was seen in some patients. As a consequence of this interaction, lower plasma&nbsp;<br />concentrations can occur, which could affect the efficacy of quetiapine therapy.&nbsp;<br />&nbsp;<br />Co-administration of quetiapine and phenytoin (another microsomal enzyme inducer) caused a&nbsp;<br />greatly increased clearance of quetiapine by approximately 450%. In patients receiving a&nbsp;<br />hepatic enzyme inducer, initiation of quetiapine treatment should only occur if the physician&nbsp;<br />considers that the benefits of quetiapine outweigh the risks of removing the hepatic enzyme&nbsp;<br />inducer. It is important that any change in the inducer is gradual, and if required, replaced&nbsp;<br />with a non-inducer (e.g. sodium valproate) (see section 4.4).&nbsp;<br />&nbsp;<br />The pharmacokinetics of quetiapine were not significantly altered by co-administration of the&nbsp;<br />antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4&nbsp;<br />and CYP 2D6 inhibitor).&nbsp;<br />&nbsp;<br />The pharmacokinetics of quetiapine were not significantly altered by co-administration of the&nbsp;<br />antipsychotics risperidone or haloperidol. Concomitant use of quetiapine and thioridazine&nbsp;<br />caused an increased clearance of quetiapine with approx. 70%.&nbsp;<br />&nbsp;<br />The pharmacokinetics of quetiapine were not altered following co-administration with&nbsp;<br />cimetidine. The pharmacokinetics of lithium were not altered when co-administered with&nbsp;<br />quetiapine.</p><p>The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically&nbsp;<br />relevant extent when co-administered. A retrospective study of children and adolescents who&nbsp;<br />received valproate, quetiapine, or both, found a higher incidence of leucopenia and&nbsp;<br />neutropenia in the combination group versus the monotherapy groups.&nbsp;<br />&nbsp;<br />Formal interaction studies with commonly used cardiovascular medicinal products have not&nbsp;<br />been performed.&nbsp;<br />&nbsp;<br />Caution should be exercised when quetiapine is used concomitantly with medicinal products&nbsp;<br />known to cause elec<br />trolyte imbalance or to increase QT-interval.&nbsp;<br />&nbsp;<br />There have been reports of false positive results in enzyme immunoassays for methadone and&nbsp;<br />tricyclic antidepressants in patients who have taken quetiapine. Confirmation of questionable&nbsp;<br />immunoassay screening results by an appropriate chromatographic technique is&nbsp;<br />recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />&nbsp;<br />Pregnancy category C&nbsp;<br />&nbsp;<br />The safety and efficacy of quetiapine during human pregnancy have not yet been established.&nbsp;<br />Up to now there are no indications for harmfulness in animal tests, possible effects on the&nbsp;<br />foetal eye have not been examined, though. Therefore, quetiapine should only be used during&nbsp;<br />pregnancy if the benefits justify the potential risks. Following pregnancies in which&nbsp;<br />quetiapine was used, neonatal withdrawal symptoms were observed.&nbsp;<br />&nbsp;<br />Neonates exposed to antipsychotics, including quetiapine, during the third trimester of&nbsp;<br />pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal&nbsp;<br />symptoms that may vary in severity and duration following delivery. There have been reports&nbsp;<br />of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding&nbsp;<br />disorder. Consequently, newborns should be monitored carefully.&nbsp;<br />&nbsp;<br /><u>Breastfeeding&nbsp;</u><br />There have been published reports of quetiapine excretion into human breast milk, however&nbsp;<br />the degree of excretion was not consistent. Women who are breast-feeding should therefore&nbsp;<br />be advised to avoid breast-feeding while taking quetiapine.&nbsp;&nbsp;<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given its primary central nervous system effects, quetiapine may interfere with activities&nbsp;<br />requiring mental alertness. Therefore, patients should be advised not to drive or operate&nbsp;<br />machinery, until individual susceptibility to this is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine are&nbsp;<br />somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic&nbsp;<br />hypotension, and dyspepsia.&nbsp;<br />&nbsp;<br />As with other antipsychotics, weight gain, syncope, neuroleptic malignant syndrome,&nbsp;<br />leukopenia, neutropenia and peripheral oedema, have been associated with quetiapine.&nbsp;<br />&nbsp;<br />The incidences of ADRs associated with quetiapine therapy, are tabulated below according to&nbsp;<br />the format recommended by the Council for International Organizations of Medical Scie<br />nces&nbsp;<br />(CIOMS III Working Group 1995).&nbsp;<br />&nbsp;<br />The frequencies of adverse events are ranked according to the following: Very common&nbsp;<br />(&gt;1/10), common (&gt;1/100 to &lt;1/10), uncommon (&gt;1/1,000 to &lt;1/100), rare (&gt;1/10,000 to&nbsp;<br />&lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="1" cellpadding="1" style="width:520px"><tbody><tr><td style="width:247px"><strong>Blood and lymphatic system disorders&nbsp;</strong><br />Very common:&nbsp;<br />&nbsp;<br />&nbsp;<br />Common: &nbsp;<br />&nbsp;<br />&nbsp;<br />Uncommon:&nbsp;<br />&nbsp;<br />Rare:&nbsp;<br />&nbsp;<br />Not known:&nbsp;<br />&nbsp;</td><td style="width:271px">Decreased haemoglobin 23&nbsp;<br />&nbsp;&nbsp;<br />Leukopenia 1,27, decreased neutrophil count,&nbsp;<br />eosinophils increased 28&nbsp;<br />&nbsp;<br />Thrombocytopenia, anaemia, platelet count&nbsp;<br />decreased 14&nbsp;<br />Agranulocytosis 29&nbsp;<br />&nbsp;<br />Neutropenia</td></tr><tr><td style="width:247px"><strong>Immune system disorders&nbsp;</strong><br />Uncommon:&nbsp;<br />&nbsp;<br />Very rare:&nbsp;<br />&nbsp;</td><td style="width:271px">Hypersensitivity (including allergic skin&nbsp;<br />reactions)&nbsp;<br />Anaphylactic reaction&nbsp;6</td></tr><tr><td style="width:247px"><p><strong>Endocrine disorders:&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;<br />&nbsp;</p><p><br />Uncommon: &nbsp;</p><p><br />Very Rare:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p></td><td style="width:271px"><p>Hyperprolactinaemia&nbsp;16, decreases in total T4&nbsp;25, decreases in free T4&nbsp;25, decreases in total&nbsp;T3&nbsp;25, increases in TSH&nbsp;25&nbsp;</p><p><br />Decreases in free T3&nbsp;25, hypothyroidism&nbsp;22<br />&nbsp;<br />Inappropriate antidiuretic hormone secretion</p></td></tr><tr><td style="width:247px"><p><strong>Metabolism and nutrition disorders</strong></p><p>Very common:</p><p>&nbsp;</p><p>&nbsp;</p><p>Common:</p><p>&nbsp;</p><p>Uncommon:</p><p>&nbsp;</p><p>&nbsp;</p><p>Rare:</p></td><td style="width:271px"><p>Elevations in serum triglycerides levels 11, 31, elevations in total cholesterol (predominantly LDL cholesterol) 12,31, decreases in HDL cholesterol 18, 31, weight gain 9, 31</p><p>&nbsp;</p><p>Increased appetite, blood glucose increased to hyperglycaemic levels 7, 31</p><p>&nbsp;</p><p>Hyponatraemia 20, diabetes mellitus 1, 5, 6</p><p>&nbsp;</p><p>&nbsp;</p><p>Metabolic syndrome</p></td></tr><tr><td style="width:247px"><strong>Psychiatric disorders&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;<br />&nbsp;<br />Rare:&nbsp;<br />&nbsp;</td><td style="width:271px">Abnormal dreams and nightmares, Suicidal&nbsp;<br />ideation and suicidal behavior.&nbsp;<br />&nbsp;<br />Somnambulism and related reactions such as&nbsp;<br />sleep talking and sleep related eating disorder.</td></tr><tr><td style="width:247px"><strong>Nervous system disorders&nbsp;</strong><br />Very common:&nbsp;<br />&nbsp;<br />Common:&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />Uncommon:&nbsp;</td><td style="width:271px"><p>&nbsp;</p><p>Dizziness&nbsp;4, 17, somnolence&nbsp;2, 17, headache&nbsp;<br />&nbsp;<br />Syncope&nbsp;4, 17, extrapyramidal symptoms&nbsp;1,&nbsp;22, dysarthria&nbsp;<br />&nbsp;<br />Seizure, Restless legs syndrome, Tardive&nbsp;<br />dyskinesia</p></td></tr><tr><td style="width:247px"><strong>Cardiac disorders&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;<br />Uncommon:&nbsp;<br />&nbsp;<br />&nbsp;</td><td style="width:271px">Tachycardia&nbsp;4, palpitations&nbsp;24<br />&nbsp;<br />&nbsp;<br />QT prolongation&nbsp;1, 13, 19<br />&nbsp;<br />Bradycardia&nbsp;33</td></tr><tr><td style="width:247px"><strong>Eye disorders&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;<br />&nbsp;</td><td style="width:271px">Vision blurred</td></tr><tr><td style="width:247px"><strong>Vascular disorders&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;<br />Rare:&nbsp;</td><td style="width:271px">Orthostatic hypotension&nbsp;4, 17<br />&nbsp;<br />Venous thromboembolism&nbsp;1</td></tr><tr><td style="width:247px"><strong>Respiratory, thoracic and mediastinal&nbsp;<br />disorders&nbsp;</strong><br />Common:&nbsp;<br />&nbsp;</td><td style="width:271px">&nbsp;<br />Rhinitis, dyspnoea&nbsp;24<br />&nbsp;</td></tr><tr><td style="width:247px"><p><strong>Gastrointestinal disorders&nbsp;</strong></p><p><br />Very common:&nbsp;<br />&nbsp;<br />Common:&nbsp;<br />&nbsp;<br />Uncommon:&nbsp;<br />&nbsp;<br />Rare:&nbsp;<br />&nbsp;</p></td><td style="width:271px"><p>Dry mouth&nbsp;<br />&nbsp;<br />Constipation, dyspepsia, vomiting&nbsp;26<br />&nbsp;<br />Dysphagia&nbsp;8&nbsp;<br />&nbsp;<br />Pancreatitis&nbsp;1</p></td></tr><tr><td style="width:247px"><strong>Hepato-biliary disorders&nbsp;</strong><br />&nbsp;<br />Common:&nbsp;<br />&nbsp;<br />&nbsp;<br />&nbsp;<br />Rare:&nbsp;<br />&nbsp;<br />&nbsp;</td><td style="width:271px">Elevations in serum transaminases, alanine&nbsp;<br />and aspartate aminotransferase (ALT, AST)&nbsp;3<br />, elevations in gamma-GT levels&nbsp;3<br />&nbsp;<br />&nbsp;<br />Jaundice&nbsp;6, hepatitis</td></tr><tr><td style="width:247px"><strong>Skin and subcutaneous tissue disorders&nbsp;</strong><br />&nbsp;<br />Very rare:&nbsp;<br />&nbsp;<br />Not known:&nbsp;<br />&nbsp;</td><td style="width:271px">Angioedema&nbsp;6, Stevens-Johnson syndrome6<br />&nbsp;<br />&nbsp;&nbsp;<br />Toxic epidermal necrolysis, erythema&nbsp;<br />multiforme</td></tr><tr><td style="width:247px"><strong>Musculoskeletal and connective tissue&nbsp;<br />disorders&nbsp;</strong><br />&nbsp;<br />Very rare:&nbsp;<br />&nbsp;</td><td style="width:271px"><br />&nbsp;<br />Rhabdomyolysis</td></tr><tr><td style="width:247px"><strong>Pregnancy, puerperium and perinatal&nbsp;<br />conditions&nbsp;</strong><br />&nbsp;<br />Not known:&nbsp;<br />&nbsp;<br />&nbsp;</td><td style="width:271px">Drug withdrawal syndrome neonatal&nbsp;32</td></tr><tr><td style="width:247px"><strong>Reproductive system and breast disorders&nbsp;</strong><br />&nbsp;<br />Uncommon:&nbsp;<br />&nbsp;<br />Rare:&nbsp;<br />&nbsp;<br />&nbsp;</td><td style="width:271px">Sexual dysfunction&nbsp;<br />&nbsp;<br />Priapism, galactorrhoea, breast swelling,&nbsp;<br />menstrual disorder</td></tr><tr><td style="width:247px"><p><strong>General disorders and administration site conditions</strong></p><p>Very common:</p><p>&nbsp;</p><p>Common:</p><p>&nbsp;</p><p>Rare:</p></td><td style="width:271px"><p>&nbsp;</p><p>&nbsp;</p><p>Withdrawal (discontinuation) symptoms 1, 10</p><p>&nbsp;</p><p>Mild asthenia, peripheral oedema, irritability, pyrexia</p><p>&nbsp;</p><p>Neuroleptic malignant syndrome1, hypothermia</p></td></tr><tr><td style="width:247px"><strong>Investigations&nbsp;</strong><br />Rare:&nbsp;<br />&nbsp;</td><td style="width:271px">Elevations in blood creatine phosphokinase&nbsp;15</td></tr></tbody></table><p>(1) See section 4.4</p><p>(2) Somnolence may occur, usually during the first two weeks of treatment and generally resolves with the continued administration of quetiapine.</p><p>(3) Asymptomatic elevations (shift from normal to &gt; 3X ULN at any time) in serum transaminase (ALT, AST) or gamma-GT levels have been observed in some patients administered quetiapine. These elevations were usually reversible on continued quetiapine treatment.</p><p>(4) As with other antipsychotics with alpha-1 adrenergic blocking activity, quetiapine may commonly induce orthostatic hypotension, associated with dizziness,</p><p>tachycardia and, in some patients, syncope, especially during the initial dose titration period (see section 4.4).</p><p>(5) Exacerbation of pre-existing diabetes has been reported in very rare cases.</p><p>(6) Calculation of frequency for these ADRs originates from post-marketing data.</p><p>(7) Fasting blood glucose 126mg/dL ( 7.0 mmol/L) or a non fasting blood glucose 200mg/dL ( 11.1 mmol/L) on at least one occasion.</p><p>(8) An increase in the rate of dysphagia with quetiapine vs. placebo was only observed in the clinical trials in bipolar depression.</p><p>(9) Based on &gt;7% increase in body weight from baseline. Occurs predominantly during the early weeks of treatment in adults.</p><p>(10) The following withdrawal symptoms have been observed most frequently in acute placebo- controlled, monotherapy clinical trials, which evaluated discontinuation symptoms: insomnia, nausea, headache, diarrhoea, vomiting, dizziness, and irritability. The incidence of these reactions had decreased significantly after 1 week post-discontinuation.</p><p>(11) Triglycerides &ge;200 mg/dL (&ge;2.258 mmol/L) (patients &ge;18 years of age) or &ge;150 mg/dL (&ge;1.694 mmol/L) (patients &lt;18 years of age) on at least one occasion.</p><p>&nbsp;</p><p>(12) Cholesterol &ge;240 mg/dL (&ge;6.2064 mmol/L) (patients &ge;18 years of age) or &ge;200 mg/dL (&ge;5.172 mmol/L) (patients &lt;18 years of age) on at least one occasion. An increase in LDL cholesterol of &ge;30 mg/dL (&ge;0.769 mmol/L) has been very commonly observed. Mean change among patients who had this increase was 41.7 mg/dL (&ge;1.07 mmol/L).</p><p>(13) See text below.</p><p>(14) Platelets &le;100 x 109/L on at least one occasion.</p><p>(15) Based on clinical trial adverse event reports of blood creatine phosphokinase increase not associated with neuroleptic malignant syndrome.</p><p>(16) Prolactin levels (patients&gt;18 years of age): &gt;20 &micro;g/L (&gt;869.56 pmol/L) males; &gt;30 &micro;g/L (&gt;1304.34 pmol/L) females at any time.</p><p>(17) May lead to falls.</p><p>(18) HDL cholesterol: &lt;40 mg/dL (1.025 mmol/L) males; &lt;50 mg/dL (1.282 mmol/L) females at any time.</p><p>(19) Incidence of patients who have a QTc shift from &lt;450 msec to &ge;450 msec with a &ge;30 msec increase. In placebo-controlled trials with quetiapine the mean change and the incidence of patients who have a shift to a clinically significant level is similar between quetiapine and placebo.</p><p>(20) Shift from &gt;132 mmol/L to &le;132 mmol/L on at least one occasion.</p><p>(21) Cases of suicidal ideation and suicidal behaviours have been reported during quetiapine therapy or early after treatment discontinuation (see Sections 4.4 and 5.1).</p><p>(22) See section 5.1</p><p>(23) Decreased haemoglobin to &le;13 g/dL (8.07 mmol/L) males, &le;12 g/dL (7.45 mmol/L) females on at least one occasion occurred in 11% of quetiapine patients in all trials including open label extensions. For these patients, the mean maximum decrease in haemoglobin at any time was &minus;1.50 g/dL.</p><p>(24) These reports often occurred in the setting of tachycardia, dizziness, orthostatic hypotension, and/or underlying cardiac/respiratory disease.</p><p>(25) Based on shifts from normal baseline to potentially clinically important value at</p><p>anytime post- baseline in all trials. Shifts in total T4, free T4, total T3 and free T3 are defined as &lt;0.8 x LLN (pmol/L) and shift in TSH is &gt;5 mIU/L at any time.</p><p>(26) Based upon the increased rate of vomiting in elderly patients (&ge;65 years of age).</p><p>(27) Shift in neutrophils from &gt;=1.5 x 109/L at baseline to &lt;0.5 x 109/L at any time during treatment.</p><p>(28) Based on shifts from normal baseline to potentially clinically important value at anytime post-baseline in all trials. Shifts in eosinophils are defined as &gt;1x109 cells/L at any time.</p><p>(29) Based on shifts from normal baseline to potentially clinically important value at anytime post- baseline in all trials. Shifts in WBCs are defined as &le;3X109cells/L at any time.</p><p>(30) Based on adverse event reports of metabolic syndrome from all clinical trials with quetiapine.</p><p>(31) In some patients, a worsening of more than one of the metabolic factors of weight, blood glucose and lipids was observed in clinical studies (See section 4.4).</p><p>(32) See section 4.6.</p><p>(33) May occur at or near initiation of treatment and be associated with hypotension and/or syncope.</p><p>Frequency based on adverse event reports of bradycardia and related events in all clinical trials with quetiapine.</p><p>&nbsp;</p><p>Cases of QT prolongation, ventricular arrhythmia, sudden unexplained death, cardiac arrest and torsades de pointes have been reported with the use of neuroleptics and are considered class effects.</p><p>&nbsp;</p><p>Children and adolescents (10 to 17 years of age)</p><p>The same ADRs described above for adults should be considered for children and adolescents. The following table summarises ADRs that occur in a higher frequency category in children and adolescents patients (10-17 years of age) than in the adult population or ADRs that have not been identified in the adult population.</p><p>&nbsp;</p><p>The frequencies of adverse events are ranked according to the following: Very common (&gt;1/10), common (&gt;1/100 to &lt;1/10), uncommon (&gt;1/1,000 to &lt;1/100), rare (&gt;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data)</p><table border="1" cellspacing="1" cellpadding="1" style="width:505px"><tbody><tr><td colspan="2">Metabolism and nutritional disorders</td></tr><tr><td>Very common:</td><td style="width:255px">Increased appetite</td></tr><tr><td colspan="2">Investigations</td></tr><tr><td>Very common:</td><td style="width:255px">Elevations in prolactin 1, increases in blood pressure 2</td></tr><tr><td colspan="2">Nervous system disorder</td></tr><tr><td>Very common:</td><td style="width:255px">Extrapyramidal symptoms 3</td></tr><tr><td colspan="2">General disorders and administration site conditions</td></tr><tr><td>Common:</td><td style="width:255px">Irritability 4</td></tr></tbody></table><p>(1) Prolactin levels (patients &lt; 18 years of age):&gt;20 ug/L (&gt;869.56 pmol/L) males;&gt;26 ug/L (&gt;1130.428 pmol/L) females at any time. Less than 1% of patients had an increase to a prolactin level&gt;100 ug/L.</p><p>(2) Based on shifts above clinically significant thresholds (adapted from the National Institutes of Health criteria) or increases&gt;20 mmHg for systolic or&gt;10 mmHg for diastolic blood pressure at any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.</p><p>(3) See section 5.1.</p><p>(4) Note: The frequency is consistent to that observed in adults, but irritability might be associated with different clinical implications in children and adolescents as compared to adults.</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>To report any side effect(s):</p><p>- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fatal outcome has been reported in clinical trials following an acute overdose at 13.6 grams,&nbsp;<br />and in post-marketing on doses as low as 6 grams of quetiapine alone. However, survival has&nbsp;<br />also been reported following acute overdoses of up to 30 grams. In post-marketing&nbsp;<br />experience, there have been reports of overdose of quetiapine alone resulting in death or&nbsp;<br />coma. Additionally, the following events have been reported in the setting of monotherapy&nbsp;<br />overdose with quetiapine: QT-prolongation, seizures, status epilepticus, rhabdomyolysis,&nbsp;<br />respiratory depression, urinary retention, confusion, delirium, and/or agitation.&nbsp;</p><p>Patients with pre-existing severe cardiovascular disease may be at an increased risk of the&nbsp;<br />effects of overdose. (See section 4.4: Cardiovascular).&nbsp;<br />&nbsp;<br />In general, reported signs and symptoms were those resulting from an exaggeration of the&nbsp;<br />active substance&#39;s known pharmacological effects, i.e., drowsiness and sedation, tachycardia&nbsp;<br />and hypotension.&nbsp;<br />&nbsp;<br /><u>Management of overdose</u><br />&nbsp;<br />&nbsp;<br />There is no specific antidote to quetiapine. In cases of severe signs, the possibility of&nbsp;<br />multiple drug involvement should be considered, and intensive care procedures are&nbsp;<br />recommended, including establishing and maintaining a patent airway, ensuring adequate&nbsp;<br />oxygenation and ventilation, and monitoring and support of the cardiovascular system.&nbsp;<br />Whilst the prevention of absorption in overdose has not been investigated, gastric lavage can&nbsp;<br />be indicated in severe poisonings and if possible to perform within one hour of ingestion.<br />&nbsp;<br />The administration of activated charcoal should be considered.&nbsp;<br />&nbsp;<br />In cases of quetiapine overdose, refractory hypotension should be treated with appropriate&nbsp;<br />measures such as intravenous fluids and/or sympathomimetic agents. Epinephrine and&nbsp;<br />dopamine should be avoided, since beta stimulation may worsen hypotension in the setting of&nbsp;<br />quetiapine-induced alpha blockade.&nbsp;<br />&nbsp;<br />Close medical supervision and monitoring should be continued until the patient recovers.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics; Diazepines, oxazepines, thiazepines and oxepines. ATC code: N 05 AH 04</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Quetiapine is an atypical antipsychotic agent. Quetiapine and the active human plasma metabolite, norquetiapine interact with a broad range of neurotransmitter receptors. Quetiapine and norquetiapine exhibit affinity for brain serotonin (5HT2) and dopamine D1 and D2 receptors. It is this combination of receptor antagonism with a higher selectivity for 5HT2 relative to D2 receptors, which is believed to contribute to the clinical antipsychotic properties and low extrapyramidal side effects (EPS) liability of quetiapine compared to typical antipsychotics. Additionally, norquetiapine has high affinity for the norepinephrine transporter (NET). Quetiapine and norquetiapine also have high affinity at histaminergic and adrenergic &alpha;1 receptors, with a lower affinity at adrenergic &alpha;2 and serotonin 5HT1A</p><p>receptors. Quetiapine has no appreciable affinity at muscarinic or benzodiazepine receptors.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Quetiapine is active in tests for antipsychotic activity, such as conditioned avoidance. It also blocks the action of dopamine-agonists, measured either behaviourally or electrophysiologically, and elevates dopamine metabolite-concentrations, a neurochemical index of D2 receptor blockade.</p><p>&nbsp;</p><p>In pre-clinical tests predictive of EPS, quetiapine is unlike typical antipsychotics and has an atypical profile. Quetiapine does not produce dopamine D2 receptor super-sensitivity after chronic administration. Quetiapine produces only weak catalepsy at effective dopamine D2 receptor blocking doses. Quetiapine demonstrates selectivity for the limbic system by producing depolarization blockade of the mesolimbic but not the nigrostriatal dopamine-containing neurones following chronic administration. Quetiapine exhibits minimal dystoni liability in haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration (see section 4.8).</p><p>&nbsp;</p><p><u><strong>Clinical efficacy</strong></u></p><p><em>Schizophrenia</em></p><p>In three placebo-controlled clinical trials, in patients with schizophrenia, using variable doses of quetiapine, there were no differences between quetiapine and placebo treatment groups in the incidence of EPS or concomitant use of anticholinergics. A placebo-controlled trial, evaluating fixed doses of quetiapine across the range of 75 to 750 mg/day, showed no evidence of an increase in EPS or the use of concomitant anticholinergics. The long-term efficacy of immediate-release quetiapine in prevention of schizophrenic relapses has not been verified in blinded clinical trials. In open label trials, in patients with schizophrenia, quetiapine was effective in maintaining the clinical improvement during continuation therapy in patients who showed an initial treatment response, suggesting some long-term efficacy.</p><p>&nbsp;</p><p><em>Bipolar Disorder</em></p><p>In four placebo-controlled clinical trials, evaluating doses of quetiapine up to 800 mg/day for the treatment of moderate to severe manic episodes, two each in monotherapy and as combination therapy to lithium or divalproex, there were no differences between the quetiapine and placebo treatment groups in the incidence of EPS or concomitant use of anticholinergics.</p><p>&nbsp;</p><p>In the treatment of moderate to severe manic episodes, quetiapine demonstrated superior efficacy to placebo in reduction of manic symptoms at 3 and 12 weeks, in two monotherapy trials. There are no data from long-term studies to demonstrate quetiapine&rsquo;s effectiveness in preventing subsequent manic or depressive episodes. Quetiapine data in combination with divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited; however, combination therapy was well tolerated. The data showed an additive effect at week 3. A second study did not demonstrate an additive effect at week 6.</p><p>&nbsp;</p><p>The mean last week median dose of quetiapine in responders was approximately 600 mg/day and approximately 85% of the responders were in the dose range of 400 to 800 mg per day.</p><p>&nbsp;</p><p>In 4 clinical trials with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, immediate-release quetiapine 300 mg and 600 mg was significantly superior to placebo treated patients for the relevant outcome measures: mean improvement on the MADRS and for response defined as at least a 50% improvement in MADRS total score from baseline. There was no difference in magnitude of effect between the patients who received 300 mg immediate-release quetiapine and those who received 600 mg dose.</p><p>&nbsp;</p><p>In the continuation phase in two of these studies, it was demonstrated that long-term treatment, of patients who responded on immediate-release quetiapine 300 or 600 mg, was efficacious compared to placebo treatment with respect to depressive symptoms, but not with regard to manic symptoms.</p><p>&nbsp;</p><p>In two recurrence prevention studies evaluating quetiapine in combination with mood stabilizers, in patients with manic, depressed or mixed mood episodes, the combination with quetiapine was superior to mood stabilizers monotherapy in increasing the time to recurrence of any mood event (manic, mixed or depressed). Quetiapine was administered twice-daily totalling 400 mg to 800 mg a day as combination therapy to lithium or valproate.</p><p>&nbsp;</p><p>In one long-term study (up to 2 years treatment) evaluating recurrence prevention in patients with manic, depressed or mixed mood episodes quetiapine was superior to placebo in increasing the time to recurrence of any mood event (manic, mixed or depressed), in patients with bipolar I disorder. The number of patients with a mood event was 91 (22.5%) in the quetiapine group, 208 (51.5%) in the placebo group and 95 (26.1%) in the lithium treatment groups respectively. In patients who responded to quetiapine, when comparing continued treatment with quetiapine to switching to lithium, the results indicated that a switch to lithium treatment does not appear to be associated with an increased time to recurrence of a mood event.</p><p>&nbsp;</p><p>Clinical trials have demonstrated that quetiapine is effective in schizophrenia and mania when given twice a day, although quetiapine has a pharmacokinetic half-life of approximately 7 hours. This is further supported by the data from a positron emission tomography (PET) study, which identified that for quetiapine, 5HT2 and D2 receptor occupancy is maintained for up to 12 hours. The safety and efficacy of doses greater than 800 mg/day have not been evaluated.</p><p>&nbsp;</p><p><u>Clinical safety</u></p><p>In short-term, placebo-controlled clinical trials in schizophrenia and bipolar mania the aggregated incidence of extrapyramidal symptoms was similar to placebo (schizophrenia: 7.8% for quetiapine and 8.0% for placebo; bipolar mania: 11.2% for quetiapine and 11.4% for placebo). Higher rates of extrapyramidal symptoms were seen in quetiapine treated patients compared to those treated with placebo in short-term, placebo-controlled clinical trials in MDD and bipolar depression. In short-term, placebo-controlled bipolar depression trials the aggregated incidence of extrapyramidal symptoms was 8.9% for quetiapine compared to 3.8% for placebo. In short-term, placebo-controlled monotherapy clinical trials in major depressive disorder the aggregated incidence of extrapyramidal symptoms was</p><p>5.4% for prolonged-release quetiapine and 3.2% for placebo. In a short-term placebo-controlled monotherapy trial in elderly patients with major depressive disorder, the aggregated incidence of extrapyramidal symptoms was 9.0% for prolonged-release quetiapine and 2.3% for placebo. In both bipolar depression and MDD, the incidence of the individual adverse events (eg, akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia, restlessness, muscle contractions involuntary, psychomotor hyperactivity and muscle rigidity) did not exceed 4% in any treatment group.</p><p>&nbsp;</p><p>In short term, fixed dose (50 mg/d to 800 mg/d), placebo-controlled studies (ranging from 3 to</p><p>8 weeks), the mean weight gain for quetiapine-treated patients ranged from 0.8 kg for the 50</p><p>mg daily dose to 1.4 kg for the 600 mg daily dose (with lower gain for the 800 mg daily dose), compared to 0.2 kg for the placebo treated patients. The percentage of quetiapine treated patients who gained &ge;7% of body weight ranged from 5.3% for the 50 mg daily dose to 15.5% for the 400 mg daily dose (with lower gain for the 600 and 800 mg daily doses), compared to 3.7% for placebo treated patients.</p><p>&nbsp;</p><p>Longer term relapse prevention trials had an open label period (ranging from 4 to 36 weeks) during which patients were treated with quetiapine, followed by a randomized withdrawal period during which patients were randomized to quetiapine or placebo. For patients who were randomized to quetiapine, the mean weight gain during the open label period was 2.56 kg, and by week 48 of the randomized period, the mean weight gain was 3.22 kg, compared to open label baseline. For patients who were randomized to placebo, the mean weight gain during the open label period was 2.39 kg, and by week 48 of the randomized period the mean weight gain was 0.89 kg, compared to open label baseline.</p><p>&nbsp;</p><p>In placebo-controlled studies in elderly patients with dementia-related psychosis, the incidence of cerebrovascular adverse events per 100 patient years was not higher in quetiapine-treated patients than in placebo-treated patients.</p><p>&nbsp;</p><p>In all short-term placebo-controlled monotherapy trials in patients with a baseline neutrophil count &ge;1.5 X 109/L, the incidence of at least one occurrence of a shift to neutrophil count &lt;1.5 X 109/L, was 1.9% in patients treated with quetiapine compared to 1.3% in placebo-treated patients. The incidence of shifts to &gt;0.5-&lt;1.0 x 109/L was the same (0.2%) in patients treated with quetiapine as with placebo- treated patients. In all clinical trials (placebo-controlled, open-label, active comparator) in patients with a baseline neutrophil count &ge;1.5 X 109/L, the incidence of at least one occurrence of a shift to neutrophil count &lt;1.5 x 109/L was 2.9% and to &lt;0.5 X 109/L was 0.21% in patients treated with quetiapine.</p><p>&nbsp;</p><p>Quetiapine treatment was associated with dose-related decreases in thyroid hormone levels. The incidences of shifts in TSH were 3.2% for quetiapine versus 2.7% for placebo. The incidence of reciprocal, potentially clinically significant shifts of both T3 or T4 and TSH in these trials were rare, and the observed changes in thyroid hormone levels were not associated with clinically symptomatic hypothyroidism.</p><p>The reduction in total and free T4 was maximal within the first six weeks of quetiapine treatment, with no further reduction during long-term treatment. For about 2/3 of all cases, cessation of quetiapine treatment was associated with a reversal of the effects on total and free T4, irrespective of the duration of treatment.</p><p>&nbsp;</p><p><u>Cataracts/lens opacities</u></p><p>In a clinical trial to evaluate the cataractogenic potential of quetiapine (200-800 mg/day) versus risperidone (2-8 mg) in patients with schizophrenia or schizoaffective disorder, the percentage of patients with increased lens opacity grade was not higher in quetiapine (4%) compared with risperidone (10%), for patients with at least 21 months of exposure.</p><p>&nbsp;</p><p><u>Paediatric population</u> (10 to 17 years of age)</p><p>The efficacy and safety of quetiapine was studied in a 3-week placebo controlled study for the treatment of mania (n=284 patients from the US, aged 10-17). About 45% of the patient population had an additional diagnosis of ADHD. In addition, a 6-week placebo controlled study for the treatment of schizophrenia (n=222 patients, aged 13-17) was performed. In both studies, patients with known lack of response to quetiapine were excluded. Treatment with quetiapine was initiated at 50 mg/day and on day 2 increased to 100 mg/day; subsequently the dose was titrated to a target dose (mania 400- 600 mg/day; schizophrenia 400-800 mg/day) using increments of 100 mg/day given two or three times daily.</p><p>&nbsp;</p><p>In the mania study, the difference in LS mean change from baseline in YMRS total score (active minus placebo) was &ndash;5.21 for quetiapine 400 mg/day and &ndash;6.56 for quetiapine 600 mg/day. Responder rates (YMRS improvement &ge;50%) were 64% for quetiapine 400 mg/day, 58% for 600 mg/day and 37% in the placebo arm.</p><p>&nbsp;</p><p>In the schizophrenia study, the difference in LS mean change from baseline in PANSS total score (active minus placebo) was &ndash;8.16 for quetiapine 400 mg/day and &ndash;9.29 for quetiapine 800 mg/day. Neither low dose (400 mg/day) nor high dose regimen (800 mg/day) quetiapine was superior to placebo with respect to the percentage of patients achieving response, defined as &ge;30% reduction from baseline in PANSS total score. Both in mania and schizophrenia higher doses resulted in numerically lower response rates.</p><p>&nbsp;</p><p>No data are available on maintenance of effect or recurrence prevention in this age group.</p><p>&nbsp;</p><p>A 26-week open-label extension to the acute trials (n=380 patients), with quetiapine flexibly</p><p>&nbsp;</p><p>dosed at 400-800 mg/day, provided additional safety data. Increases in blood pressure were reported in children and adolescents and increased appetite, extrapyramidal symptoms and elevations in serum prolactin were reported with higher frequency in children and adolescents than in adult patients (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><em>Extrapyramidal symptoms</em></p><p>In a short-term placebo-controlled monotherapy trial with quetiapine in adolescent patients (13-17 years of age) with schizophrenia, the aggregated incidence of extrapyramidal symptoms was 12.9% for quetiapine and 5.3% for placebo, though the incidence of the individual adverse events (e.g. akathisia, tremor, extrapyramidal disorder, hypokinesia, restlessness, psychomotor hyperactivity, muscle rigidity, dyskinesia) did not exceed 4.1% in any treatment group. In a short-term placebo-controlled monotherapy trial with quetiapine in children and adolescent patients (10-17 years of age) with bipolar mania, the aggregated incidence of extrapyramidal symptoms was 3.6% for quetiapine and 1.1% for placebo. In a long-term open label study with quetiapine of schizophrenia and bipolar mania, the aggregated incidence of treatment-emergent EPS was 10%.</p><p>&nbsp;</p><p><em>Weight Gain</em></p><p>In short-term clinical trials with quetiapine in paediatric patients (10-17 years of age), 17% of quetiapine treated patients and 2.5% of placebo treated patients gained &ge;7% of</p><p>their body weight.</p><p>When adjusting for normal growth over longer term, an increase of at least 0.5 standard deviation from baseline in Body Mass Index (BMI) was used as a measure of a clinically significant change; 18.3% of patients who were treated with quetiapine for at least 26 weeks met this criterion.</p><p>&nbsp;</p><p><em>Suicide/Suicidal thoughts or Clinical worsening</em></p><p>In short-term placebo-controlled clinical trials with quetiapine in paediatric patients with</p><p>schizophrenia, the incidence of suicide related events was 1.4% (2/147) for quetiapine and 1.3% (1/75) for placebo in patients &lt;18 years of age. In short-term placebo-controlled trials with quetiapine in paediatric patients with bipolar mania, the incidence of suicide related events was 1.0% (2/193) for quetiapine and 0% (0/90) for placebo in patients &lt;18 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Quetiapine is well absorbed and extensively metabolised following oral administration. The bioavailability of quetiapine is not significantly affected by administration with food.</p><p>Steady-state peak molar concentrations of the active metabolite norquetiapine are 35% of that observed for quetiapine.</p><p>The pharmacokinetics of quetiapine and norquetiapine are linear across the approved dosing range.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Quetiapine is approximately 83% bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Quetiapine is extensively metabolised by the liver, with parent compound accounting for less than 5% of unchanged drug-related material in the urine or faeces, following the administration of radiolabelled quetiapine. In vitro investigations established that CYP3A4 is the primary enzyme responsible for cytochrome P450 mediated metabolism of quetiapine. Norquetiapine is primarily formed and eliminated via CYP3A4.</p><p>Approximately 73% of the radioactivity is excreted in the urine and 21% in the faeces.</p><p>&nbsp;</p><p>Quetiapine and several of its metabolites (including norquetiapine) were found to be weak inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro. In vitro CYP inhibition is observed only at concentrations approximately 5 to 50 fold higher than those observed at a dose range of 300 to 800 mg/day in humans. Based on these in vitro results, it is unlikely that co- administration of quetiapine with other drugs will result in clinically significant drug inhibition of cytochrome P450 mediated metabolism of the other drug.</p><p>From animal-studies it appears that quetiapine can induce cytochrome P450 enzymes. In a specific interaction study in psychotic patients, however, no increase in the cytochrome P450 activity was found after administration of quetiapine.</p><p><u>Elimination</u></p><p>The elimination half lives of quetiapine and norquetiapine are approximately 7 and 12 hours, respectively. The average molar dose fraction of free quetiapine and the active human plasma metabolite norquetiapine is &lt;5% excreted in the urine.</p><p>&nbsp;</p><p><u><em>Special populations</em></u></p><p>&nbsp;</p><p>Gender</p><p>The kinetics of quetiapine do not differ between men and women.</p><p>&nbsp;</p><p>Elderly</p><p>The mean clearance of quetiapine in the elderly is approximately 30 to 50% lower than that seen in adults aged 18 to 65 years.</p><p>&nbsp;</p><p>Renal Impairment</p><p>The mean plasma clearance of quetiapine was reduced by approximately 25% in subjects with severe renal impairment (creatinine clearance less than 30 ml/min/1.73m2), but the individual clearance values are within the range for normal subjects.</p><p>&nbsp;</p><p>Hepatic Impairment</p><p>The mean quetiapine plasma clearance decreases with approx. 25% in persons with known hepatic impairment (stable alcohol cirrhosis). As quetiapine is extensively metabolised by the liver, elevated plasma levels are expected in the population with hepatic impairment. Dose adjustments may be necessary in these patients (see section 4.2).</p><p>&nbsp;</p><p>Children and adolescents (10 to 17 years of age)</p><p>Pharmacokinetic data were sampled in 9 children aged 10-12 years old and 12 adolescents, who were on steady-state treatment with 400 mg quetiapine twice daily. At steady-state, the dose-normalised plasma levels of the parent compound, quetiapine, in children and adolescents (10-17 years of age) were in general similar to adults, though Cmax in children was at the higher end of the range observed in adults. The AUC and Cmax for the active metabolite, norquetiapine, were higher, approximately 62% and 49% in children (10-12 years), respectively and 28% and 14% in adolescents (13-17 years), respectively, compared to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of genotoxicity in a series of in vitro and in vivo genotoxicity studies. In laboratory animals at a clinically relevant exposure level the following deviations were seen, which as yet have not been confirmed in long-term clinical research:</p><p>In rats, pigment deposition in the thyroid gland has been observed; in cynomolgus monkeys thyroid follicular cell hypertrophy, a lowering in plasma T3 levels, decreased haemoglobin concentration and a decrease of red and white blood cell count have been observed; and in dogs lens opacity and cataracts. (For cataracts/lens opacities see section 5.1).</p><p>Taking these findings into consideration, the benefits of the treatment with quetiapine</p><p>need to be balanced against the safety risks for the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:<br />Cellulose, microcrystalline<br />Povidone K29-32<br />Calcium hydrogen phosphate dihydrate Sodium starch glycolate (type A) Lactose<br />monohydrate<br />Magnesium stearate<br />Tablet coating: Hypromellose 6cP (E 464) Titanium dioxide (E 171) Lactose monohydrate<br />Macrogol 3350<br />Triacetin<br />Iron oxide yellow E172 (in 25 mg, 100 mg and 150 mg) Iron oxide red E172 (only in 25 mg)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs (PVC/PVDC/Al blisters, PVC/Al blisters) Tablet containers (HDPE)<br />Pack sizes:<br />Blisters:<br />Qatpen 25 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets<br />Qatpen 100 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets<br />Qatpen 150 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets<br />Qatpen 200 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets<br />Qatpen 300 mg film-coated tablets: 6, 10, 20, 30, 50, 60, 90, 100 tablets</p><p>Tablet containers:<br />Qatpen 25 mg film-coated tablets: 100, 250 tablets<br />Qatpen 100 mg film-coated tablets: 100, 250 tablets<br />Qatpen 150 mg film-coated tablets: 100, 250 tablets<br />Qatpen 200 mg film-coated tablets: 100, 250 tablets<br />Qatpen 300 mg film-coated tablets: 60, 100, 250 tablets<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturerd by
SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation
P.O. Box 2597 Al-Qassim First Industrial City,
King AbdulAzziz Road, BURAYDAH 51461,
Al-Qassim, Saudi Arabia.
For
Dammam Pharma
Saudi Arabia
Address: 1st industrial city, unit No.1, PO.BOX: 7137, Dammam 32234-4384
Phone: +966138472944
Fax: +966138474182
Email: regulatory-affairs@dammampharma.sa
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>